Lower respiratory tract disorder
MONDO:0000270A disease involving the lower respiratory tract.
Also known as: disease of lower respiratory tract, disease or disorder of lower respiratory tract, disorder of lower respiratory tract, lower respiratory tract disease, lower respiratory tract disease or disorder
7938 clinical trials for this condition and its sub-types, 18 tagged with Lower respiratory tract disorder itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Lower respiratory tract disorder
-
Lung disorder 251 trials · 7,078 incl. sub-types
33 sub-types
- Lung neoplasm 1,367 trials · 4,039 incl. sub-types Sub-types →
- Obstructive lung disease 36 trials · 1,071 incl. sub-types Sub-types →
- Respiratory failure 279 trials · 789 incl. sub-types Sub-types →
- Interstitial lung disease 256 trials · 728 incl. sub-types Sub-types →
- Pneumonitis 15 trials · 645 incl. sub-types Sub-types →
- Bronchiolitis 51 trials · 104 incl. sub-types Sub-types →
- Acute lung injury 90 trials
- Fungal lung infectious disease 6 trials · 57 incl. sub-types Sub-types →
- Pulmonary non-tuberculous mycobacterial infection 48 trials
- Aspiration pneumonia 33 trials
- Acute chest syndrome 30 trials
- Middle lobe syndrome 29 trials
- Pulmonary systemic sclerosis 27 trials
- Pulmonary coin lesion 24 trials
- Pulmonary alveolar proteinosis 9 trials · 13 incl. sub-types Sub-types →
- Pulmonary artery disease 12 trials
- Rheumatoid arthritis-associated interstitial lung disease 12 trials
- Occupational lung disease 4 trials · 8 incl. sub-types Sub-types →
- Restrictive pulmonary disease 8 trials
- Neonatal aspiration syndrome 1 trial · 6 incl. sub-types Sub-types →
- Lung abscess 3 trials
- Pneumonic plague 3 trials
- Hantavirus pulmonary syndrome 2 trials
- Pulmonary immaturity 2 trials
- Wilson-Mikity syndrome 0 trials
- Dystrophic pulmonary ossification 0 trials
- Pulmonary alveolar microlithiasis 0 trials
- Pulmonary embolism and infarction 0 trials
- Pulmonary plasma cell granuloma 0 trials
- Pulmonary venoocclusive disease 0 trials Sub-types →
- Shrinking lung syndrome 0 trials
- Silo filler disease 0 trials
- Vanishing lung syndrome 0 trials
-
Tracheal disorder 6 trials · 1,088 incl. sub-types
8 sub-types
- Chronic obstructive pulmonary disease 935 trials · 1,051 incl. sub-types Sub-types →
- Tracheal stenosis 20 trials
- Tracheitis 2 trials · 7 incl. sub-types Sub-types →
- Congenital tracheomalacia 6 trials
- Trachea neoplasm 2 trials · 5 incl. sub-types Sub-types →
- Isolated tracheo-esophageal fistula 2 trials
- Laryngotracheoesophageal cleft 1 trial Sub-types →
- Tracheal calcification 0 trials
-
Bronchial disorder 19 trials · 1,010 incl. sub-types
6 sub-types
- Asthma 724 trials · 819 incl. sub-types Sub-types →
- Bronchiectasis 118 trials · 119 incl. sub-types Sub-types →
- Bronchitis 24 trials · 50 incl. sub-types Sub-types →
- Bronchial neoplasm 20 trials · 38 incl. sub-types Sub-types →
- Non-syndromic bridging bronchus 0 trials
- Non-syndromic congenital bronchial atresia 0 trials
-
Pleural disorder 15 trials · 177 incl. sub-types
5 sub-types
- Pleural neoplasm 5 trials · 97 incl. sub-types Sub-types →
- Pneumothorax 35 trials · 45 incl. sub-types Sub-types →
- Pleural empyema 20 trials Sub-types →
- Pleurisy 2 trials · 9 incl. sub-types Sub-types →
- Congenital chylothorax 0 trials
-
Tracheobronchitis 5 trials · 55 incl. sub-types
2 sub-types
- Bronchitis 24 trials · 50 incl. sub-types Sub-types →
- Tracheitis 2 trials · 7 incl. sub-types Sub-types →
Most studied deeper sub-types
Showing the 400 most recently updated of 3047 trials in this tab.
-
Can a Three-Drug cocktail before surgery stop small cell lung cancer from returning?
Cure Recruiting nowResearchers are testing whether giving adebrelimab, apatinib mesylate, and chemotherapy before surgery helps people with limited-stage small cell lung cancer. The study enrolls adults with early-stage disease that surgeons can remove. Participants receive the drug combination for…
Phase 2 • Sponsor: Jin Ying • Aim: Cure
Last updated Sep 13, 2026 00:00 UTC
-
Off-the-Shelf immune cells target solid tumors
Cure Recruiting nowResearchers are testing a new cell therapy called CAR001 in adults with solid tumors that have come back or stopped responding to standard treatment. CAR001 uses donor gamma-delta T cells engineered with a chimeric antigen receptor to recognize and attack cancer cells. The trial …
Phase 1/2 • Sponsor: Ever Supreme Bio Technology Co., Ltd. • Aim: Cure
Last updated Sep 11, 2026 00:00 UTC
-
New drug combo aims to tame tough lung cancer
Disease control Recruiting nowThis study tests a new drug combination (alisertib plus paclitaxel) in people with small cell lung cancer who have already tried other treatments. The main goal is to find safe doses and see what side effects occur. About 50 adults will take alisertib pills and receive paclitaxel…
Phase 2 • Sponsor: Puma Biotechnology, Inc. • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Could an immunotherapy drug keep early lung cancer from returning?
Disease control Recruiting nowThis phase III trial is testing whether the immunotherapy drug atezolizumab, given after surgery, can prevent stage I non-small cell lung cancer from returning. About 336 patients who have had their tumor completely removed will be randomly assigned to receive either atezolizumab…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Lifeline for cancer patients: rollover study extends access to targeted drug opnurasib
Disease control Recruiting nowThis rollover study allows up to 40 people with KRAS G12C-mutated lung or other solid tumors who are already benefiting from opnurasib in a Novartis trial to keep receiving the drug. Participants continue their current dose of opnurasib alone or with TNO155 or trametinib. The goa…
Phase 1/2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Poop pills? stool transplants may ease immunotherapy side effects
Disease control Recruiting nowThis early-stage trial tests whether a stool transplant (FMT) can help cancer patients who develop severe diarrhea or colon inflammation from immune-checkpoint inhibitor drugs. About 40 patients with various cancers will receive the transplant via colonoscopy. The main goal is to…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New study tests if asthma drug can stop symptoms Long-Term
Disease control Recruiting nowThis study follows 335 adults with severe eosinophilic asthma who are taking benralizumab. Researchers want to see if the drug helps patients achieve partial or complete clinical remission—meaning fewer symptoms, no need for steroid pills, and better lung function—over 12 to 24 m…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug targets Hard-to-Treat lung cancer in early trial
Disease control Recruiting nowThis phase 2 trial tests a drug called navlimetostat in about 130 people with advanced or metastatic non-small cell lung cancer that has a specific genetic change (MTAP deletion) and has worsened after other treatments. The main goal is to see if the drug can shrink tumors. Resea…
Phase 2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug rilvegostomig takes on keytruda in lung cancer showdown
Disease control Recruiting nowThis phase 3 study compares two immunotherapy drugs—rilvegostomig and pembrolizumab (Keytruda)—each combined with standard chemotherapy, as a first treatment for people with advanced squamous non-small cell lung cancer that has a specific protein (PD-L1). About 880 participants w…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Experimental pill SHY-ONC6 takes on Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests an experimental oral drug called SHY-ONC6 in people with advanced or metastatic solid tumors (including breast, colon, lung, pancreatic, and others) that have stopped responding to standard treatments. The study aims to find a safe dose and check for …
Phase 1 • Sponsor: SHY Therapeutics • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New mRNA vaccine combo aims to prevent lung cancer recurrence in High-Risk patients
Disease control Recruiting nowThis phase 3 trial tests whether a personalized mRNA cancer vaccine (intismeran) alone or combined with an immunotherapy drug (pembrolizumab) can prevent non-small cell lung cancer from coming back after complete surgical removal. About 876 people with high-risk stage I lung canc…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can a new drug ASP388B take on advanced solid tumors?
Disease control Recruiting nowThis trial tests an experimental drug called ASP388B, given alone or alongside standard cancer therapies, in people with advanced solid tumors that have spread or cannot be removed by surgery. The study has two parts: the first finds a safe dose, and the second tests that dose in…
Phase 1/2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can a COPD inhaler also help your heart?
Disease control Recruiting nowThis study tests a triple-combination inhaler (budesonide, glycopyrronium, and formoterol) against a placebo in 56 people with COPD and lung hyperinflation. The goal is to see if the inhaler improves both lung function and heart function, measured by MRI. Participants will receiv…
Phase 4 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New pill targets Hard-to-Treat cancers with RAS mutations
Disease control Recruiting nowThis study tests an experimental oral drug, BPI-572270, in 120 adults with advanced solid tumors (lung, colorectal, or pancreatic cancer) that have specific RAS gene mutations. The trial has two phases: first to find a safe dose and check for side effects, then to see if the drug…
Phase 1/2 • Sponsor: Betta Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can a single inhaler outperform adding extra medications for asthma?
Disease control Recruiting nowThis study looks at whether switching from a rescue inhaler (albuterol) to a combination inhaler (albuterol/budesonide) is better at preventing severe asthma attacks than adding another daily controller medication while keeping albuterol. Researchers will analyze health records f…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug trial aims to improve lung function in fibrosis patients
Disease control Recruiting nowThis study tests a new medicine called BI 765423 in 71 adults with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring and breathing problems. Participants receive either the drug or a placebo by infusion every four weeks for about 3 months. The main goal is …
Phase 2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New hope for Hard-to-Treat lung cancer? osimertinib trial launches
Disease control Recruiting nowThis phase II trial is testing the drug osimertinib in 46 people with advanced non-small cell lung cancer that has a specific genetic change (EGFR exon 20 insertion). The goal is to see if the drug can shrink tumors or slow the cancer's growth. Participants will take osimertinib …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New lung cancer drug ivonescimab takes on pembrolizumab in major trial
Disease control Recruiting nowThis phase 3 study compares ivonescimab, an experimental immunotherapy, to the standard drug pembrolizumab in 780 people with advanced non-small cell lung cancer that has high PD-L1 levels. Participants receive one of the two drugs as their first treatment. The study measures how…
Phase 3 • Sponsor: Summit Therapeutics • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers with genetic weakness
Disease control Recruiting nowThis early-stage trial is testing a new drug called IDE892, alone or with another drug (IDE397), in people with advanced solid tumors that have a specific genetic deletion (MTAP). The study aims to find safe doses and see if the drugs shrink tumors. It includes 260 adults with ca…
Phase 1 • Sponsor: IDEAYA Biosciences • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New antibody AU-007 enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called AU-007 in people with advanced solid tumors that have spread or cannot be removed by surgery. The drug is designed to help the immune system fight cancer. About 159 participants will receive AU-007 alone or with other medicines to find the safes…
Phase 1/2 • Sponsor: Aulos Bioscience, Inc. • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can donated immune cells calm the cytokine storm?
Disease control Recruiting nowResearchers are testing whether regulatory T cells taken from donated thymus tissue can control the dangerous immune overreaction that occurs in severe COVID-19 and acute respiratory distress syndrome (ARDS). The trial enrolls adults aged 18 to 65 who are hospitalized with acute …
Phase 1/2 • Sponsor: Hospital General Universitario Gregorio Marañon • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New pill aims to cut dangerous lung Flare-Ups in bronchiectasis
Disease control Recruiting nowThis study tests a daily pill called BI 1291583 (Verducatib) in 1755 adults and teens with bronchiectasis, a lung condition causing frequent infections and coughing. Participants take either the drug or a placebo for up to 76 weeks. The main goal is to see if the drug reduces the…
Phase 3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Lung cancer vaccine trial aims to stop tumors from coming back
Disease control Recruiting nowThis study tests whether adding an experimental mRNA vaccine (V940) to the immunotherapy drug pembrolizumab (Keytruda) can keep lung cancer from returning after surgery. It includes 680 people with stage II to IIIB non-small cell lung cancer whose tumors did not fully respond to …
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New hope for ALK lung cancer: first human trial of AQUA07 begins
Disease control Recruiting nowThis early-stage trial tests a new oral drug called AQUA07, alone or with another drug (lorlatinib), in about 102 people with ALK-positive non-small cell lung cancer that has spread or cannot be removed. The main goals are to check safety, find the right dose, and see how the bod…
Phase 1 • Sponsor: Chugai Pharmaceutical • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New combo therapy aims to shrink lung tumors without chemo or surgery
Disease control Recruiting nowThis study tests a drug called NBTXR3 given with radiation therapy for people with locally-advanced non-small cell lung cancer who cannot have chemotherapy or surgery. The goal is to see if the combination is safe and helps control the cancer. About 40 adults with stage I to III …
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancers with genetic weakness
Disease control Recruiting nowThis study tests a new drug, TER-2013, in people with advanced solid tumors (like breast, ovarian, or lung cancer) that have specific genetic changes in the AKT/PI3K/PTEN pathway. The goal is to see if the drug is safe and can shrink tumors. About 205 participants will receive th…
Phase 1/2 • Sponsor: Terremoto Biosciences Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can a simple shot replace an IV for this aggressive lung cancer?
Disease control Recruiting nowThis phase 3 trial is testing whether tarlatamab, an immunotherapy drug, can be given as a quick injection under the skin instead of a slow intravenous drip for people with relapsed extensive-stage small cell lung cancer. The study will compare the two methods to see if the injec…
Phase 3 • Sponsor: Amgen • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug combo aims to outperform standard care in aggressive lung cancer
Disease control Recruiting nowThis Phase 3 trial will test whether a new drug called BL-M14D1 combined with atezolizumab works better than the current standard treatment for people with extensive-stage small cell lung cancer who have not had prior therapy. About 550 adults will be randomly assigned to receive…
Phase 3 • Sponsor: SystImmune Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Experimental drug combo aims to extend cancer control in lung cancer
Disease control Recruiting nowThis trial tests whether adding the experimental drug iadademstat to standard immunotherapy (atezolizumab or durvalumab) can help keep extensive-stage small cell lung cancer from growing. About 45 adults whose cancer responded to initial chemo-immunotherapy will receive the combi…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New pill targets Hard-to-Treat lung cancer mutation
Disease control Recruiting nowThis trial tests an experimental daily pill, VS-7375, for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12D. Participants must have already tried chemotherapy and an immunotherapy drug. The study looks at whether the drug can shri…
Phase 2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New chemo formula aims to keep lung cancer away after surgery
Disease control Recruiting nowThis study tests a drug called SMS001, a new version of the chemotherapy paclitaxel, in 42 people with non-small cell lung cancer (stages Ib to IIIa). The goal is to see if a single dose after surgery can safely prevent the cancer from coming back. Researchers will monitor side e…
Phase 2 • Sponsor: ToLymph Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Foam plug could open door to lung valve therapy for thousands
Disease control Recruiting nowThis study tests a foam called AeriSeal that is squirted into damaged parts of the lung to block tiny air leaks. After the foam, doctors check if the lung is now sealed enough to place a one-way valve that lets trapped air escape. The goal is to help people with severe emphysema …
Sponsor: Pulmonx Corporation • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Smart bombs for lung cancer: new ADC drugs enter trial
Disease control Recruiting nowThis phase 2 trial tests two antibody-drug conjugates (ADCs) — R-DXD and I-DXD — against standard chemotherapy in 144 people with advanced squamous non-small cell lung cancer that has worsened after initial treatment. ADCs are like guided missiles that deliver a cancer-killing dr…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Could an immune booster keep early lung cancer from returning?
Disease control Recruiting nowThis phase 3 trial is testing whether the immunotherapy drug durvalumab, given after surgery, can prevent early-stage non-small cell lung cancer from coming back. About 306 participants who have had their tumor completely removed will be randomly assigned to receive durvalumab or…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New combo therapy aims to extend life in advanced lung cancer
Disease control Recruiting nowThis phase 3 trial tests whether adding the experimental drug MK-2870 to the standard immunotherapy pembrolizumab helps people with advanced non-small cell lung cancer live longer compared to pembrolizumab alone. The study enrolls about 614 adults whose tumors have high PD-L1 lev…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancers in large trial
Disease control Recruiting nowThis phase 2 trial is testing an experimental drug called patritumab deruxtecan (HER3-DXd) in 740 people with advanced solid tumors, including melanoma, lung, breast, and other cancers. The drug is given by IV every three weeks. The main goal is to see if the drug shrinks tumors.…
Phase 2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New pill aims to keep HER2 lung cancer from returning after surgery
Disease control Recruiting nowThis study tests whether a daily pill called zongertinib can help prevent lung cancer from coming back in people with early-stage (Stage II-IIIB) non-small cell lung cancer that has a specific HER2 mutation. All participants have had surgery to remove their tumor and standard che…
Phase 3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New Antibody-Drug conjugate IM-1617 enters human trials for advanced cancers
Disease control Recruiting nowThis early-stage trial is testing a new drug called IM-1617 in people with advanced solid tumors (cancers that have spread or can't be removed by surgery). The study has two parts: first, finding a safe dose, then testing that dose in more people to see how well it works and how …
Phase 1 • Sponsor: Immunome, Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New cancer drug GI-108 enters human trials for advanced tumors
Disease control Recruiting nowThis study tests a new drug called GI-108 in people with advanced or metastatic solid tumors, including lung, head and neck, pancreatic, and kidney cancers. The drug is designed to boost the immune system's ability to fight cancer. The trial will first find the safest dose, then …
Phase 1/2 • Sponsor: GI Innovation, Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
AI-Designed drug targets scarred lungs in major trial
Disease control Recruiting nowThis phase 3 trial tests whether the oral drug rentosertib (INS018_055) can slow lung function decline in adults with idiopathic pulmonary fibrosis (IPF), a progressive lung disease. About 320 participants will receive either rentosertib or a placebo daily for 52 weeks. The main …
Phase 3 • Sponsor: InSilico Medicine Hong Kong Limited • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Gut bacteria may boost lung cancer therapy
Disease control Recruiting nowThis study tests whether taking special gut bacteria capsules (RMT) alongside standard chemotherapy and immunotherapy can help control advanced lung cancer. About 82 people with untreated non-small cell lung cancer will receive either RMT or a placebo. The goal is to see if the b…
Phase 2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New hope for lung scarring? drug trial aims to slow breathing decline
Disease control Recruiting nowThis study tests two doses of an experimental drug, zampilimab, against a placebo in 240 adults with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. The main goal is to see if the drug can improve lung function over 24 weeks, with an …
Phase 2 • Sponsor: Chiesi Farmaceutici S.p.A. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New combo therapy takes on advanced cancers
Disease control Recruiting nowThis early-stage study tests a new drug called N-3C01, given alone or with an immunotherapy, in people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety, find the right dose, and see if the combination shrinks tumors. About 114 a…
Phase 1/2 • Sponsor: Hefei Xinzhu Biological Technology Co., Ltd. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Breathing machine settings put to the test in severe lung injury
Disease control Recruiting nowAcute respiratory distress syndrome (ARDS) is a life-threatening lung injury that often requires a breathing machine. This trial compares two ways of using that machine: airway pressure release ventilation (APRV), which holds the lungs open longer with brief releases, and convent…
Sponsor: Hospital Civil de Guadalajara • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Radioactive 'Smart Bomb' targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase trial is testing a new radioactive drug that seeks out a protein called Nectin-4 found on many cancer cells. The drug delivers a dose of radiation directly to the tumor, aiming to destroy it while sparing healthy tissue. About 150 adults with advanced bladder, br…
Phase 1 • Sponsor: Aktis Oncology, Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug combo aims to keep lung cancer in check longer
Disease control Recruiting nowThis Phase 2 trial tests whether combining lurbinectedin (Zepzelca) with durvalumab (Imfinzi) as maintenance therapy can delay cancer growth in people with extensive-stage small-cell lung cancer whose disease has not worsened after initial chemotherapy plus durvalumab. About 50 p…
Phase 2 • Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Radioactive drug takes on standard therapy in lung cancer trial
Disease control Recruiting nowThis phase II trial tests whether a radioactive drug called lutetium Lu 177 dotatate works better than the usual drug everolimus for people with advanced bronchial neuroendocrine tumors (a type of lung cancer). The radioactive drug targets a protein on tumor cells and delivers ra…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New hope for stage 4 lung cancer: experimental combo therapy enters global trial
Disease control Recruiting nowThis study tests whether adding an experimental drug (EIK1001) to standard immunotherapy and chemotherapy helps people with stage 4 non-small cell lung cancer live longer or slow tumor growth. About 750 adults whose cancer has spread will receive either the new combination or a p…
Phase 2/3 • Sponsor: Eikon Therapeutics • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug targets Hard-to-Treat lung cancer mutation in major trial
Disease control Recruiting nowThis study tests a new drug, setidegrasib, against a standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer that has a specific KRAS G12D mutation. The goal is to see if setidegrasib can keep the cancer from growing longer and help people live longer…
Phase 3 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New combo therapy aims to control advanced lung cancer
Disease control Recruiting nowThis study tests a new drug called YL201 combined with atezolizumab in people with advanced small cell lung cancer. The goal is to find safe doses and see if the combination helps control the disease. About 118 adults who have not had prior treatment for this cancer will take par…
Phase 1/2 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New combo aims to stop lung cancer return after surgery
Disease control Recruiting nowThis study tests whether adding the drug MK-2870 to standard immunotherapy (pembrolizumab) after surgery can help prevent lung cancer from coming back. It is for people with stage II to IIIB non-small cell lung cancer whose tumor did not fully disappear after chemotherapy and imm…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Could everyday heart drugs shield cancer patients from Radiation's cardiac toll?
Disease control Recruiting nowThis study tests whether two common heart medications—atorvastatin (a statin) and lisinopril (an ACE inhibitor)—can prevent or reduce heart damage caused by radiation therapy for chest cancers like breast, lung, and esophageal cancer. About 60 adults receiving chest radiation wil…
Phase 2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can a malaria drug help sarcoidosis patients ditch steroids?
Disease control Recruiting nowThis study tests if hydroxychloroquine, a drug used for malaria and autoimmune diseases, can help people with sarcoidosis reduce or stop taking steroids. Sarcoidosis causes inflammation, often in the lungs, but this trial focuses on cases affecting the skin, eyes, or bones. 140 a…
Phase 4 • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers: experimental drug targets KRAS mutation
Disease control Recruiting nowThis early-phase trial is testing a new oral drug called RMC-5127, alone or combined with other drugs, in adults with advanced solid tumors that have a specific KRAS G12V mutation. The study includes people with lung, colorectal, and pancreatic cancers who have already tried stan…
Phase 1 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Proton beams aimed at lung tumors while sparing the heart
Disease control Recruiting nowResearchers at Emory University are testing intensity-modulated proton therapy (IMPT) for people with small cell lung cancer. Proton therapy delivers radiation to tumors while reducing exposure to nearby healthy organs like the heart. The study enrolls 30 adults with limited or e…
Sponsor: Emory University • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New antibody HT31-1 enters human trials for ARDS
Disease control Recruiting nowThis early-stage trial tests a new antibody called HT31-1 in 24 healthy volunteers to see if it is safe and how the body processes it. The antibody targets a protein linked to inflammation in acute respiratory distress syndrome (ARDS), a severe lung condition often caused by infe…
Phase 1 • Sponsor: HTIC, Inc • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New hope for advanced cancers? first human trial launches
Disease control Recruiting nowThis early-stage study is testing a new drug called BGB-B2033, alone or with other drugs, in people with advanced liver, stomach, or lung cancers. The goal is to see if it is safe and how well it works. About 392 participants will take part.
Phase 1/2 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Experimental gene therapy aims to revive lung cancer treatment
Disease control Recruiting nowThis study tests an experimental gene therapy called quaratusugene ozeplasmid (Reqorsa) combined with the drug osimertinib (Tagrisso) in people with advanced EGFR-mutant non-small cell lung cancer whose cancer has stopped responding to osimertinib alone. The gene therapy delivers…
Phase 1/2 • Sponsor: Genprex, Inc. • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New device aims to help ventilator patients breathe easier by scrubbing CO2 from blood
Disease control Recruiting nowThis study tests a device called PrismaLung+ that removes carbon dioxide from the blood of critically ill patients who are on breathing machines. The trial will include 99 adults with acute respiratory distress syndrome or kidney injury. Half will receive standard care plus the d…
Sponsor: Vantive Health LLC • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can a soy compound shield lungs from radiation damage?
Disease control Recruiting nowThis phase II trial tests whether a drug called BIO 300, made from a soy compound, can prevent severe lung inflammation (pneumonitis) in people with early-stage non-small cell lung cancer who also have interstitial lung disease. About 25 participants will receive BIO 300 along wi…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Breathing exercises may cut hospital stays for babies with bronchiolitis
Disease control Recruiting nowThis study tests whether outpatient respiratory physiotherapy can prevent hospitalizations in infants up to 12 months old with mild to moderate acute viral bronchiolitis. The therapy includes gentle airway clearance techniques and, if needed, continuous positive airway pressure (…
Sponsor: University of Sao Paulo • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New weekly shot could fight deadly mould infections with fewer side effects
Disease control Recruiting nowThis Phase 2 trial tests whether a new drug called EL219 (Turletricin) is safe and effective for early treatment of invasive mould infections in people with weakened immune systems, such as those who have had a bone marrow transplant. About 60 participants will receive either EL2…
Phase 2 • Sponsor: Elion Therapeutics, Inc. • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Texting your doctor: a simple app could save lives after lung screening
Disease control Recruiting nowThis study tests whether using a chat-based mobile app (Zalo) can help people follow through with recommended tests after an abnormal chest X-ray read by AI. About 2,692 adults in Vietnam at risk for lung cancer or TB will be randomly assigned to receive either standard results o…
Sponsor: Gia Dinh People Hospital • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can a pill shrink Hard-to-Treat ovarian tumors?
Disease control Recruiting nowResearchers are testing a new oral drug called DC05F01 in adults with recurrent ovarian cancer and other advanced solid tumors that have worsened after standard treatment. The trial aims to see how well the drug shrinks tumors, how long it keeps cancer from growing, and what side…
Phase 1/2 • Sponsor: Heronova Pharmaceuticals • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New targeted drug shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug called BG-C9074, designed to target and kill cancer cells in people with advanced solid tumors that have not responded to standard treatments. The study will first find the safest dose, then test it alone or with other cancer drugs. About 3…
Phase 1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Precision radiation aims to stop lung cancer return after surgery
Disease control Recruiting nowThis phase 2 trial tests proton beam radiation therapy in 20 adults with non-small cell lung cancer that has spread to chest lymph nodes (N2) and has been surgically removed. Proton therapy targets cancer cells while sparing healthy tissue, potentially reducing recurrence risk. R…
Phase 2 • Sponsor: Emory University • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug cocktail targets Hard-to-Treat cancers with genetic flaw
Disease control Recruiting nowThis early-phase trial is testing an experimental drug called BMS-986504 alongside standard cancer treatments in 60 people with advanced cancers that have lost a gene called MTAP. The cancers include mesothelioma, stomach/esophageal cancer, and bladder cancer. The main goal is to…
Phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Two-Drug cocktail aims to boost chemo against tough lung cancer
Disease control Recruiting nowThis phase 2 trial tests whether adding two experimental drugs, imzokitug and pumitamig, to standard chemotherapy helps people with advanced non-small cell lung cancer (NSCLC) who have not had prior treatment. About 160 participants will receive either the three-drug combination …
Phase 2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug aims to halt lung damage in autoimmune patients
Disease control Recruiting nowThis study tests whether the drug nerandomilast can slow lung scarring in people with autoimmune diseases like rheumatoid arthritis or scleroderma. About 400 adults whose lung function hasn't improved with standard treatment will take either nerandomilast or a placebo twice daily…
Phase 3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New pill targets Hard-to-Treat cancers: early trial recruits 554 patients
Disease control Recruiting nowThis study tests an experimental oral drug called S241656 (BDTX-4933) in people with advanced solid tumors that have certain genetic changes (KRAS, BRAF, or other RAS/MAPK mutations). The trial has two parts: first, finding a safe dose, then testing how well it works alone or wit…
Phase 1/2 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New antibody aims to cut lung attacks in bronchiectasis patients
Disease control Recruiting nowThis study tests an experimental drug called AZD0292 in 435 people aged 12 and older who have bronchiectasis and a long-term lung infection with Pseudomonas aeruginosa. The goal is to see if the drug can reduce the number of moderate-to-severe lung flare-ups compared to a placebo…
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Could a spinal implant tame Hard-to-Control asthma?
Disease control Recruiting nowThis study tests whether a device that stimulates the spinal cord — called pulmonary neuromodulation — can improve asthma control in adults with moderate to severe asthma that remains uncontrolled despite high-dose inhalers or biologic medications. Participants receive the implan…
Sponsor: Spiro Medical, Inc. • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
DNA-Guided immunotherapy trial aims to match drug to tumor
Disease control Recruiting nowThis study tests the immunotherapy drug atezolizumab in 200 people with advanced solid tumors (breast, lung, GI, and others). Researchers use each person's tumor DNA to see if it predicts a response. Participants get the same dose every 3 weeks. The goal is to see if DNA analysis…
Phase 2 • Sponsor: British Columbia Cancer Agency • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug BL-M14D1 targets tough cancers in early human trial
Disease control Recruiting nowThis early-stage trial is testing a new drug called BL-M14D1 in about 120 people with advanced small cell lung cancer or other neuroendocrine cancers that have spread or cannot be removed. The drug works by homing in on a protein called DLL3 found on these cancer cells and delive…
Phase 1 • Sponsor: SystImmune Inc. • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
A pill that could outsmart food allergies? trial tests remibrutinib
Disease control Recruiting nowThis Phase 3 study is testing whether an oral drug called remibrutinib can help people with IgE-mediated allergies to peanuts, cow's milk, or hen's egg tolerate larger amounts of the allergen without symptoms. Adults and adolescents aged 12 to 65 will receive either the drug or a…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Supercharged immune cells take on Hard-to-Treat lung cancer
Disease control Recruiting nowThis early-stage trial is testing a new approach for people with advanced non-small cell lung cancer that has specific gene changes (EGFR, ALK, ROS1, or HER2). Doctors take immune cells from the patient's own tumor, boost them in the lab with a molecule called CD40L, and then giv…
Phase 1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New hope for hard-to-treat lung cancer: targeted drug plus immunotherapy tested
Disease control Recruiting nowThis study tests a drug called adagrasib, alone or with pembrolizumab (an immunotherapy), in people with advanced non-small cell lung cancer that has a specific genetic change (KRAS G12C). The goal is to see if the combination shrinks tumors and helps people live longer without t…
Phase 2/3 • Sponsor: Mirati Therapeutics Inc. • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Could less be more? new study tests lower doses of cancer drug
Disease control Recruiting nowThis study is testing whether giving lower, less frequent doses of the cancer drug atezolizumab can still keep enough drug in the blood to fight cancer. About 30 adults with certain advanced cancers (like lung cancer or melanoma) will start with standard doses, then switch to a l…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug tezepelumab tested for stuffy nose and polyps
Disease control Recruiting nowThis study looks at how well tezepelumab works for adults with chronic sinusitis and nasal polyps (with or without asthma). About 110 people will be followed for up to a year to see if their nasal polyps shrink and congestion improves. The goal is to understand real-world benefit…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat lung cancer
Disease control Recruiting nowThis study tests whether combining two drugs, tepotinib and ivonescimab, is safe and works for people with advanced non-small cell lung cancer that has a specific genetic change called METex14 skipping. About 16 participants will try different doses to find the one with the fewes…
Phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New hope for lung cancer: targeted drug telisotuzumab vedotin faces off against chemo
Disease control Recruiting nowThis phase 3 trial compares a new targeted drug, telisotuzumab vedotin, to the standard chemotherapy docetaxel in adults with a specific type of advanced non-small cell lung cancer that has a high level of a protein called c-Met. About 698 participants worldwide will receive eith…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can a tougher radiation schedule outpace aggressive lung tumors?
Disease control Recruiting nowResearchers are testing a radiation schedule that delivers higher doses per session and more sessions per day for non-small cell lung cancer that grows quickly. The trial enrolls adults with confirmed high-proliferation NSCLC who are planned for chest radiotherapy, regardless of …
Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New antibody WIN378 aims to tame COPD lung inflammation
Disease control Recruiting nowThis phase 2 trial is testing a new medicine called WIN378 for people with moderate to severe COPD. WIN378 is a long-acting antibody that blocks a protein involved in lung inflammation. The study will test different doses in 105 adults who are former smokers and already on standa…
Phase 2 • Sponsor: Windward Bio • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New pill takes on brain tumors and metastases in early trial
Disease control Recruiting nowThis study tests an oral drug called NEO212 in people with specific brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it helps control tumor growth. About 134 adults will take NEO212 alone or with sta…
Phase 1/2 • Sponsor: Neonc Technologies, Inc. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Can schools and doctors team up to keep kids with asthma out of the ER?
Disease control Recruiting nowResearchers are piloting REACH, a service model that connects families, schools, and healthcare providers to improve asthma care for children. The study enrolls parents and children in partner school districts, along with school nurses and providers. REACH combines asthma educati…
Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Cancer patients on targeted therapy get extended safety monitoring
Disease control Recruiting nowThis study provides continued access to dabrafenib and/or trametinib for up to 100 patients with melanoma, lung cancer, or other solid tumors who were benefiting from these drugs in a prior Novartis or GSK trial. The main goal is to track long-term side effects and safety over ti…
Phase 4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug aims to tame COPD Flare-Ups in Hard-to-Treat patients
Disease control Recruiting nowThis study tests a new drug called lunsekimig in adults aged 40-80 with COPD that is not well controlled despite standard treatments. The goal is to see if the drug can reduce the number of moderate-to-severe flare-ups over 48 weeks compared to a placebo. Participants will receiv…
Phase 3 • Sponsor: Sanofi • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Can a new biologic drug prevent COPD Flare-Ups?
Disease control Recruiting nowThis phase 2 trial tests whether galvokimig, an experimental biologic drug, can reduce the number of moderate-to-severe COPD flare-ups in people with chronic bronchitis. About 400 adults aged 40 to 80 with moderate-to-severe COPD will receive either galvokimig or a placebo as an …
Phase 2 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New shot could tame COPD Flare-Ups for those with eosinophilic lung disease
Disease control Recruiting nowThis study tests a new injectable drug called lunsekimig in about 942 adults aged 40-80 with COPD that is not well controlled, especially those with a type linked to high eosinophils (a kind of white blood cell). Participants will receive either the drug or a placebo for about 48…
Phase 3 • Sponsor: Sanofi • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New hope for aggressive lung cancer: experimental drug combo enters final testing
Disease control Recruiting nowThis study tests whether adding the experimental drug obrixtamig to standard chemotherapy and immunotherapy helps people with advanced small cell lung cancer live longer. About 670 adults with extensive-stage disease will be randomly assigned to receive either the new combination…
Phase 3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug aimed at Hard-to-Treat lung cancer enters Mid-Stage trial
Disease control Recruiting nowThis phase 2 trial is testing three different doses of an investigational drug called telisotuzumab vedotin in about 150 adults with a specific type of advanced lung cancer (non-small cell lung cancer that has high levels of a protein called c-Met and no EGFR mutation). The drug …
Phase 2 • Sponsor: AbbVie • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New combo targets tough lung cancer in early trial
Disease control Recruiting nowThis early-phase trial is testing two drugs, osimertinib and tegavivint, as a first treatment for people with a specific type of advanced lung cancer (EGFR-mutant NSCLC that has spread). The goal is to find the best dose and see if the combination is safe and shrinks tumors. Abou…
Phase 1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New pill targets rare cancer mutation in early trial
Disease control Recruiting nowThis study tests a new drug called rezatapopt (PC14586) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The drug is designed to reactivate the p53 protein, which normally helps stop cancer growth. The trial will also test rezatapopt combined with th…
Phase 1/2 • Sponsor: PMV Pharmaceuticals, Inc • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New cell therapy trial hopes to tackle tough cancers
Disease control Recruiting nowThis early-phase trial tests SL-28, a cell therapy made from donor immune cells, in 60 people with advanced solid tumors (like lung, pancreatic, or breast cancer) that haven't responded to standard treatments. The study aims to find a safe dose and see if the therapy can shrink t…
Phase 1/2 • Sponsor: Second Life Therapeutics • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Can a digital program help teens with chronic illnesses move to adult care?
Disease control Recruiting nowResearchers are testing whether a digital version of a transition program can help teenagers with chronic conditions like asthma or organ transplants move from pediatric to adult healthcare. The program includes a transition coordinator, education, peer meetings, and a personaliz…
Sponsor: Göteborg University • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Could a Low-Dose arthritis drug ease a dangerous sickle cell complication?
Disease control Recruiting nowThis phase 2 trial is testing whether a single low dose of tocilizumab, a drug that blocks inflammation, can help people with sickle cell disease who develop acute chest syndrome—a serious lung complication. Researchers will enroll 200 patients aged 12 and older and track their o…
Phase 2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Can blocking adenosine receptors help the immune system fight solid tumors?
Disease control Recruiting nowResearchers are testing two experimental oral drugs, TT-10 and TT-4, in adults with advanced solid tumors such as kidney, prostate, and lung cancers that have worsened after standard treatment or cannot receive it. The drugs block adenosine receptors, which tumors use to quiet th…
Phase 1/2 • Sponsor: Portage Biotech • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New hope for lung cancer patients whose treatment has failed
Disease control Recruiting nowThis study tests a new drug, telisotuzumab adizutecan, in people with advanced EGFR-mutated non-small cell lung cancer whose cancer has progressed after a third-generation targeted therapy. About 430 adults will receive either the new drug or standard care. The goal is to see if …
Phase 2/3 • Sponsor: AbbVie • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Cholesterol-Lowering drug may boost lung cancer immunotherapy
Disease control Recruiting nowThis phase 2 trial tests whether adding tafolecimab (a cholesterol-lowering drug) to standard chemotherapy and the immunotherapy sintilimab helps people with extensive-stage small cell lung cancer live longer without their cancer growing. About 40 adults who have not had prior tr…
Phase 2 • Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New combo aims to outperform chemo for tough lung cancer
Disease control Recruiting nowThis study tests a new combination of two drugs (trastuzumab deruxtecan and pembrolizumab) against standard chemotherapy plus pembrolizumab as a first treatment for people with advanced non-small cell lung cancer that has high levels of HER2 and low PD-L1. About 686 adults will t…
Phase 3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New hope for tough lung cancer: ABBV-706 faces off against standard care
Disease control Recruiting nowThis study tests a new drug, ABBV-706, against standard treatments for small cell lung cancer that has come back or stopped responding. About 531 adults will receive either ABBV-706 or usual care (topotecan, lurbinectedin, or amrubicin) to see which works better. The goal is to s…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Hope for kids with scarred lungs: new drug trial launches
Disease control Recruiting nowThis study tests a medicine called nerandomilast in children aged 2 to 17 with fibrosing interstitial lung disease, a condition where lung tissue becomes scarred and stiff. The goal is to see if the drug is safe and how the body processes it, and to get early signs of whether it …
Phase 3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug EVOLVE104 takes on tough cancers in early human trial
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called EVOLVE104 in people with advanced bladder cancer or several types of squamous cell carcinoma (lung, esophagus, skin, and others). The study aims to find a safe dose and see if the drug can shrink tumors. It is for pati…
Phase 1 • Sponsor: EvolveImmune United, Inc • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Could a plasma protein cut deaths in severe pneumonia?
Disease control Recruiting nowThis phase 3 trial tests whether adding trimodulin (a protein mixture from donated blood) to standard care can lower death rates in adults with severe community-acquired pneumonia who need a breathing machine. About 590 hospitalized patients will receive either trimodulin or a pl…
Phase 3 • Sponsor: Biotest • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancers with KRAS mutation
Disease control Recruiting nowThis early-stage study is testing a new drug called calderasib (MK-1084) in people with advanced solid tumors that have a specific KRAS G12C mutation. The drug is given alone or combined with other cancer treatments. The main goals are to check safety and find the right dose. Abo…
Phase 1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New lung cancer drug shows promise in early trial
Disease control Recruiting nowThis study tests a new medicine called PF-08634404, given alone or with chemotherapy, for adults with early or locally advanced non-small cell lung cancer. The trial has three parts: before surgery, after surgery if cancer remains, or after chemoradiation. Researchers will check …
Phase 2 • Sponsor: Pfizer • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New hope against deadly mold infections enters final testing
Disease control Recruiting nowThis study tests a new medicine called fosmanogepix for adults with serious mold infections that are hard to treat. About 234 people will join, receiving either the new drug or standard care. The main goal is to see if fewer people die by day 42. The study is currently recruiting…
Phase 3 • Sponsor: Basilea Pharmaceutica • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New combo therapy targets tough lung cancer in early trial
Disease control Recruiting nowThis study tests an experimental drug called BMS-986525, given alone or with the immunotherapy nivolumab (Opdivo), in 240 people whose small cell lung cancer has returned or stopped responding to standard platinum-based chemotherapy. The main goals are to check safety and tolerab…
Phase 1/2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New breathing machine approach aims to shield heart in lung failure patients
Disease control Recruiting nowThis study tests a breathing machine strategy that adjusts pressure based on lung measurements to protect the right side of the heart in 180 adults with moderate to severe lung failure from pneumonia. The goal is to see if this method reduces heart strain and complications compar…
Sponsor: Beijing Chao Yang Hospital • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
ER-to-Specialist telehealth boost could cut asthma attacks
Disease control Recruiting nowThis study tests whether arranging a telehealth appointment with an asthma specialist before patients leave the emergency room increases follow-up care. Forty adults who come to the ER for an asthma attack will either get a scheduled telehealth visit or usual care. The goal is to…
Sponsor: Juan Carlos Cardet • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New hope for tough lung cancer: targeted drug ZL-1310 enters final testing
Disease control Recruiting nowThis Phase 3 trial tests ZL-1310, a drug that delivers chemotherapy directly to cancer cells, in people with small cell lung cancer that has returned after initial treatment. About 480 participants will receive either ZL-1310 or one of three standard treatments. The study aims to…
Phase 3 • Sponsor: Zai Lab (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug combo aims to outperform standard lung cancer therapy
Disease control Recruiting nowThis phase 3 trial is testing whether a combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy works better than the current standard (pembrolizumab plus chemotherapy) for people with advanced non-squamous lung cancer whose tumors have PD-L1 levels of…
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis study is testing a new experimental drug called GI-101, given alone or with pembrolizumab or lenvatinib, in people with advanced or metastatic solid tumors (cancers that have spread). The goal is to see if the drug is safe and can shrink or control tumors. About 317 adults w…
Phase 1/2 • Sponsor: GI Innovation, Inc. • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New targeted combo aims to outsmart KRAS lung cancer
Disease control Recruiting nowThis Phase 3 trial tests whether adding the targeted drug calderasib to the immunotherapy pembrolizumab helps people with a specific KRAS G12C-mutated lung cancer live longer without their cancer growing. About 675 participants with advanced non-squamous non-small cell lung cance…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New ventilator aims to help patients breathe easier in the ICU
Disease control Recruiting nowThis trial is testing a new ventilator called INBENTUS VERSATILE in 81 adults who need help breathing. The study checks if the device is safe and works well for conditions like ARDS, pneumonia, and COPD. Participants will use the ventilator for 3 to 48 hours and be monitored unti…
Sponsor: Iconic Solutions By Murcia SL • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New combo aims to stop KRAS-Mutant lung cancer from coming back
Disease control Recruiting nowThis Phase 3 trial is testing whether adding an experimental drug called calderasib (MK-1084) to standard immunotherapy (pembrolizumab) can keep non-small cell lung cancer from returning after surgery. The study enrolls 400 people with a specific KRAS G12C mutation whose cancer w…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Inhaled drug could offer new hope for lung scarring disease
Disease control Recruiting nowThis phase 2 trial tests whether an inhaled form of nintedanib (MNKD-201) is safe and effective for people with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring. About 210 adults with IPF will receive either a low or high dose of the inhaled drug or a plac…
Phase 2 • Sponsor: Mannkind Corporation • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug cocktail targets Hard-to-Treat lung cancer subtype
Disease control Recruiting nowThis study tests whether adding a new drug called navlimetostat to standard immunotherapy (pembrolizumab) and chemotherapy helps people with a specific genetic form of advanced lung cancer (MTAP deletion) live longer without their cancer worsening. About 590 participants will be …
Phase 2/3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Global study checks if triple inhaler really works for COPD patients
Disease control Recruiting nowThis study follows 1,400 adults with moderate to severe COPD who are starting Breztri/Trixeo, a triple-combination inhaler. Researchers will track changes in symptoms and quality of life over 12 months in real-world clinics across Latin America, Asia, and the Middle East & Africa…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New hope for KRAS lung cancer: targeted pill plus immunotherapy in Late-Stage trial
Disease control Recruiting nowThis phase 3 trial tests whether adding the targeted pill calderasib (MK-1084) to the immunotherapy durvalumab helps people with a specific KRAS G12C-mutated lung cancer live longer without their cancer growing. About 310 participants who have finished chemotherapy and radiation …
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New triple therapy takes on stubborn lung cancer in early trial
Disease control Recruiting nowThis early-phase trial is testing a new oral drug called iadademstat combined with radiation therapy and the immunotherapy atezolizumab in people with extensive-stage small-cell lung cancer that has persisted, returned, or worsened after first-line treatment. The study will enrol…
Phase 1 • Sponsor: Yale University • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug cocktail targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called BMS-986507, alone or with other cancer medicines, in adults with advanced lung or breast cancer that has spread. The goal is to check safety, side effects, and how well the drugs work. About 416 participants will receive different combinations t…
Phase 1/2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Can a gene test guide better treatment for head and neck cancer survivors?
Disease control Recruiting nowThis study compares two treatments after surgery for stage III-IVA head and neck cancer: radiation alone versus radiation plus the chemotherapy drug cisplatin. The goal is to see which approach better prevents the cancer from returning, especially in patients with certain TP53 ge…
Phase 2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New smart drug targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called TUB-040 for people with ovarian cancer that no longer responds to platinum chemotherapy, or with a type of lung cancer that has come back. TUB-040 is an antibody-drug conjugate, meaning it delivers a powerful chemotherapy directly to cancer cell…
Phase 1/2 • Sponsor: Tubulis GmbH • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug cocktail aims to outperform standard lung cancer therapy
Disease control Recruiting nowThis study tests whether two experimental drugs (livmoniplimab and budigalimab) combined with chemotherapy work better than the current standard treatment (pembrolizumab plus chemo) for people with untreated metastatic non-squamous non-small cell lung cancer. About 840 adults wil…
Phase 2/3 • Sponsor: AbbVie • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Inhaled drug aims to ease dangerous lung blood pressure in scarred lungs
Disease control Recruiting nowResearchers are testing an inhaled drug called mosliciguat in people who have pulmonary hypertension caused by interstitial lung disease, a condition where lung scarring leads to high blood pressure in the lungs. The phase 3 trial enrolls about 376 participants who receive either…
Phase 3 • Sponsor: Pulmovant, Inc. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Engineered immune cells take on tough lung cancer
Disease control Recruiting nowThis study tests a new treatment called DJI136, which uses a patient's own immune cells engineered to target a protein (DLL3) found on small cell lung cancer cells. The trial enrolls 80 adults with extensive-stage small cell lung cancer whose disease has progressed after standard…
Phase 1/2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Lung cancer trial combines two treatments to outsmart resistance
Disease control Recruiting nowThis study compares the standard drug osimertinib alone versus osimertinib plus chemotherapy (carboplatin and pemetrexed) in people with metastatic EGFR-mutant lung cancer who still have detectable cancer DNA in their blood after starting osimertinib. The goal is to see if the co…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Immunotherapy after Chemo-Radiation shows promise for lung cancer
Disease control Recruiting nowThis study looks at whether the immunotherapy drug durvalumab can help people with limited-stage small-cell lung cancer when given after chemoradiation. Researchers will track 200 patients in China to see how long the cancer stays under control and how safe the treatment is. The …
Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New pill aims to slow lung scarring in IPF patients
Disease control Recruiting nowThis phase 2 trial tests an oral drug called PIPE-791 in 324 adults with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. Participants take either a low or high dose of PIPE-791 or a placebo daily for several months. The main goal is t…
Phase 2 • Sponsor: Contineum Therapeutics • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Pfizer launches early trial of PF-08634404 combo for tough lung cancers
Disease control Recruiting nowThis study tests a new experimental drug called PF-08634404 combined with other cancer medicines in people with advanced non-small cell lung cancer that has spread and can't be surgically removed. The trial has two parts: one combining PF-08634404 with sigvotatug vedotin, and ano…
Phase 1/2 • Sponsor: Pfizer • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New antibody drug combo targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called AZD8205, alone or with another drug (rilvegostomig), in people with advanced solid tumors like breast, ovarian, and lung cancers. The trial has two phases: first to find the safest dose, then to see if it shrinks tumors. About 460 adults whose c…
Phase 1/2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Can a new biologic drug delay dangerous lung Flare-Ups?
Disease control Recruiting nowThis phase 2 trial is testing whether an experimental biologic drug called galvokimig can delay the first moderate or severe lung infection (pulmonary exacerbation) in adults with non-cystic fibrosis bronchiectasis, a chronic lung condition that causes coughing, mucus buildup, an…
Phase 2 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New combo aims to boost lung cancer treatment in patients with bone metastases
Disease control Recruiting nowThis phase 2 trial tests whether adding the drug narlumosbart and precise radiation therapy to standard first-line treatment can help people with advanced non-small cell lung cancer that has spread to the bones. The study will enroll 27 adults who have not had prior systemic ther…
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug MK-4716 targets KRAS cancers in early trial
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called MK-4716, alone or combined with other cancer drugs, in people with advanced solid tumors that have a KRAS mutation. The main goal is to see if the drug is safe and tolerable. About 250 participants will be enrolled.
Phase 1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug cocktail aims to shrink lung tumors without chemo
Disease control Recruiting nowThis study tests a new drug called telisotuzumab adizutecan (ABBV-400) combined with an immunotherapy drug (budigalimab or pembrolizumab) in people with advanced non-squamous lung cancer who have not had prior treatment. The goal is to find the best dose that is safe and effectiv…
Phase 1/2 • Sponsor: AbbVie • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New triple inhaler could simplify asthma care for teens
Disease control Recruiting nowThis study tests a new once-daily inhaler called QVM149, which combines three medicines (indacaterol, glycopyrronium, and mometasone furoate) to control asthma. It will enroll 304 teenagers aged 12 to 17 and compare the new inhaler to a standard twice-daily treatment (salmeterol/…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New immunotherapy combo shows promise for tough cancers
Disease control Recruiting nowThis phase 2 trial is testing an experimental drug called volrustomig, either alone or with chemotherapy, in people with advanced cervical, head and neck, esophageal, or mesothelioma cancers. The study aims to see if the drug can shrink tumors and how safe it is. About 257 partic…
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New hope for Hard-to-Treat breast cancer: targeted drug trial begins
Disease control Recruiting nowThis early-phase study tests a new drug called BGB-43395 in people with advanced HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. Researchers want to find the safest and most effective dose, either alone or combined wi…
Phase 1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Can two drugs keep Limited-Stage lung cancer from returning?
Disease control Recruiting nowResearchers are testing whether adding tislelizumab and anlotinib after chemoradiotherapy can help people with limited-stage small cell lung cancer live longer without their cancer coming back. The study enrolls adults aged 18 to 75 whose cancer has not worsened after concurrent …
Phase 2 • Sponsor: Yantai Yuhuangding Hospital • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug combo aims to fight aggressive lung cancer
Disease control Recruiting nowThis study tests a new drug called ABBV-706 combined with the immunotherapy atezolizumab as a first treatment for people with extensive-stage small cell lung cancer, a fast-growing cancer that has spread. About 180 adults will receive either the new combination at one of two dose…
Phase 2 • Sponsor: AbbVie • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New hope for lung cancer patients with a specific gene mutation
Disease control Recruiting nowThis study tests a drug called sotorasib in people with advanced non-small cell lung cancer that has a specific change in the KRAS gene (called G12C). Participants have not yet received any treatment for their advanced cancer. The goal is to see if sotorasib is safe and effective…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New hope for aggressive lung cancer: phase 3 trial launches
Disease control Recruiting nowThis phase 3 trial is testing a new combination of drugs (BMS-986489) plus chemotherapy against a standard treatment (atezolizumab plus chemotherapy) for people with extensive-stage small cell lung cancer, a fast-growing cancer. The study aims to see if the new combo helps people…
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug TUB-030 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis trial tests a new drug called TUB-030 in adults with advanced solid tumors, including head and neck, lung, and breast cancers. The goal is to find the safest and most effective dose. Participants receive the drug every three weeks and are monitored for side effects and tumor…
Phase 1/2 • Sponsor: Tubulis GmbH • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New gene therapy combo aims to keep advanced lung cancer in check
Disease control Recruiting nowThis study tests a new gene therapy (quaratusugene ozeplasmid) plus an immunotherapy drug (atezolizumab) as maintenance treatment for people with extensive stage small cell lung cancer. The goal is to see if the combination can keep the cancer from growing longer than standard ca…
Phase 1/2 • Sponsor: Genprex, Inc. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New asthma drug could help kids breathe easier
Disease control Recruiting nowThis study tests whether tezepelumab, an injectable drug, can reduce severe asthma attacks in children aged 5 to 11 with hard-to-control asthma. About 231 kids will receive either tezepelumab or a placebo, alongside their usual asthma medicines. The main goal is to see if the dru…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug combo aims to tackle tough lung cancer
Disease control Recruiting nowThis phase 2 trial is testing two experimental drugs, ubamatamab and REGN7075, alone or together, in 300 people with advanced or metastatic non-small cell lung cancer who have already had standard treatments. A third drug, sarilumab, may be used to manage immune-related side effe…
Phase 2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Can a CXCR1/2 blocker boost radiation against cancer that spreads to the brain lining?
Disease control Recruiting nowResearchers are testing whether combining SX-682, an experimental drug that blocks CXCR1 and CXCR2, with proton craniospinal irradiation is safe and effective for people with leptomeningeal disease from melanoma or non-small cell lung cancer. Participants take SX-682 by mouth twi…
Phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New hope for tough lung cancer: targeted drug combo takes on standard care
Disease control Recruiting nowThis study tests whether a new drug combo (sotorasib plus chemotherapy) works better than the current standard (pembrolizumab plus chemotherapy) for people with advanced non-small cell lung cancer that has a specific KRAS G12C gene change and low PD-L1 levels. About 750 adults wh…
Phase 3 • Sponsor: Amgen • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New combo aims to outsmart lung Cancer's growth signals
Disease control Recruiting nowThis Phase III trial is testing whether adding bevacizumab to the standard drug osimertinib can better control advanced EGFR-mutant non-small cell lung cancer. About 300 people with stage IIIB or IV disease will be randomly assigned to receive either the combination or osimertini…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Can a new injection help tame asthma? a trial seeks answers
Disease control Recruiting nowThis trial tests an experimental drug called SKB575 in adults with asthma. The goal is to see if it is safe and whether it can improve asthma control and lung function. Participants receive either SKB575 or a placebo as a shot under the skin, and researchers monitor side effects …
Phase 1 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New asthma shot aims to help patients breathe easier
Disease control Recruiting nowThis Phase 2 trial tests an injectable drug called RC1416 in 195 adults with moderate to severe asthma that is not well controlled. Participants will receive either the drug or a placebo by injection. The study will measure changes in lung function and track asthma attacks over t…
Phase 2 • Sponsor: Nanjing RegeneCore Biotech Co., Ltd. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New targeted drug takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug, BAY 3713372, for people with solid tumors that have a specific genetic deletion called MTAP. The drug is designed to kill cancer cells while sparing normal cells. The trial will first find a safe dose, then test how well it works in up to 450 particip…
Phase 1/2 • Sponsor: Bayer • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New combo therapy targets aggressive lung cancer transformation
Disease control Recruiting nowThis phase 2 trial tests a combination of tarlatamab (a targeted immune therapy), chemotherapy, and atezolizumab in 50 adults whose lung cancer has transformed from a common type (adenocarcinoma) to a more aggressive small cell form after initial treatment. The goal is to see if …
Phase 2 • Sponsor: Sehhoon Park • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New hope for lung cancer: personalized drug cocktails before surgery
Disease control Recruiting nowThis study tests different drug combinations in people with early-stage non-small cell lung cancer that can be removed with surgery. The drugs are chosen based on specific genetic markers in each person's tumor. The goal is to see if these treatments shrink the tumor before surge…
Phase 2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New drug BL-M07D1 targets multiple HER2 cancers in early trial
Disease control Recruiting nowThis Phase 1 trial tests a new drug called BL-M07D1 in 280 adults with advanced HER2-positive cancers, including breast, lung, and stomach cancers. The study aims to find safe doses and check for early signs of tumor shrinkage. Participants must have tried at least two prior trea…
Phase 1 • Sponsor: SystImmune Inc. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New cancer drug KK2269 enters first human tests
Disease control Recruiting nowThis early-stage trial tests the safety of a new drug called KK2269, given alone or with chemotherapy (docetaxel), in adults with advanced solid tumors that have no standard treatment options. About 101 participants will take part. The study has two parts: first testing KK2269 al…
Phase 1 • Sponsor: Kyowa Kirin Co., Ltd. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New antibody EPI-326 enters first human trials for tough cancers
Disease control Recruiting nowThis early-phase study tests a new drug called EPI-326 in about 110 people with advanced lung or head & neck cancers that have specific EGFR mutations. The drug is a bispecific antibody designed to target cancer cells more precisely. The main goals are to check safety, find the r…
Phase 1 • Sponsor: EpiBiologics • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New drug aims to reduce deaths from severe lung failure
Disease control Recruiting nowThis study tests an experimental drug called recombinant human plasma gelsolin (rhu-pGSN) added to standard care for people with moderate-to-severe acute respiratory distress syndrome (ARDS) caused by pneumonia or other infections. About 600 hospitalized adults will receive eithe…
Phase 2 • Sponsor: BioAegis Therapeutics Inc. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New hope for advanced cancer: experimental drug CR-001 enters human trials
Disease control Recruiting nowThis study tests a new drug called CR-001 in adults with advanced solid tumors that have spread. The goal is to find the safest dose and see if it can shrink tumors. About 290 people will take part in this early-phase trial.
Phase 1/2 • Sponsor: Crescent Biopharma, Inc. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New antibody injection targets Hard-to-Treat lung cancer in early trial
Disease control Recruiting nowThis early-stage study tests a new drug called TQB2922, given as a shot under the skin, in 42 people with advanced non-small cell lung cancer that has not responded to standard treatments. The drug is a bispecific antibody designed to block two cancer-related proteins (EGFR and c…
Phase 1 • Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New program helps doctors prescribe better asthma treatment
Disease control Recruiting nowThis study tests a program to help doctors at community health centers prescribe a recommended asthma treatment called SMART (Single Maintenance and Reliever Therapy). The program includes training, feedback, and educational tools for both doctors and patients. Researchers will m…
Phase 4 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Antibiotic flush directly into the lungs tested against bronchiectasis Flare-Ups
Disease control Recruiting nowBronchiectasis damages the airways and causes repeated flare-ups of cough and breathlessness. Researchers are testing whether washing the affected lung areas with saline through a bronchoscope, then injecting the antibiotic amikacin directly into those areas, can delay the next f…
Sponsor: First Affiliated Hospital of Ningbo University • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Lung cancer trial seeks optimal immunotherapy schedule around surgery
Disease control Recruiting nowThis phase 3 trial compares three ways of giving the immunotherapy drug toripalimab to people with stage II-IIIA non-small cell lung cancer that can be removed with surgery. Participants will receive toripalimab either before surgery (neoadjuvant), after surgery (adjuvant), or bo…
Phase 3 • Sponsor: Fudan University • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New combo tackles Drug-Resistant lung cancer in early trial
Disease control Recruiting nowThis phase 2 trial tests whether combining two targeted drugs—lazertinib and tepotinib—can shrink tumors in people with advanced EGFR-mutant non-small cell lung cancer whose disease has worsened after initial lazertinib treatment due to MET gene changes. About 47 participants wil…
Phase 2 • Sponsor: Sehhoon Park • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New pill targets HER2 lung cancer in major trial
Disease control Recruiting nowThis Phase 3 trial is testing a new oral drug, sevabertinib, against standard intravenous chemotherapy for people with advanced non-small cell lung cancer that has specific HER2 mutations. About 444 participants will be randomly assigned to receive either sevabertinib twice daily…
Phase 3 • Sponsor: Bayer • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New drug combo aims to keep lung cancer at bay
Disease control Recruiting nowThis study tests whether adding a new drug (BL-B01D1) to the standard pill osimertinib can help people with a certain type of Stage III lung cancer stay cancer-free longer. Participants must have an EGFR gene mutation and have already completed chemotherapy and radiation without …
Phase 3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Two-Drug combo targets aggressive RET-Driven lung cancer
Disease control Recruiting nowResearchers are testing whether combining pembrolizumab, an immunotherapy given intravenously every three weeks, with lenvatinib, a daily oral drug, can help adults with metastatic non-small cell lung cancer that carries a RET gene rearrangement and has worsened after prior treat…
Phase 3 • Sponsor: EuroCityClinic LLC • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New inhaled drug KIT2014 tested for COPD – early trial begins
Disease control Recruiting nowThis study tests an inhaled drug called KIT2014 in 36 adults with moderate to severe COPD. Participants will receive either the drug or a placebo daily for 7 days. The main goal is to check safety and how the body handles the drug, with a first look at whether it might help breat…
Phase 1/2 • Sponsor: Kither Biotech Srl • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New triple inhaler could help teens with Hard-to-Control asthma
Disease control Recruiting nowThis study tests whether a triple-combination inhaler (containing three drugs) works better than a standard dual-combination inhaler for teenagers aged 12-17 whose asthma is not well controlled. About 292 participants will use either the triple or dual inhaler daily for 24 weeks.…
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New smart drug targets tough cancers in first human trial
Disease control Recruiting nowThis early-stage trial tests a new drug called M7437 in people with advanced solid tumors that have not responded to standard treatments. M7437 is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells that have a specific marker (Ly6E). The study ai…
Phase 1 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can a new drug curb COPD Flare-Ups?
Disease control Recruiting nowThis phase 3 trial is testing whether an investigational drug called felcorekibart, when added to standard COPD therapy, can reduce the number of moderate and severe flare-ups in adults aged 40 to 80 with moderate to very severe COPD. Participants will receive either felcorekibar…
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can a less extensive lung cancer surgery be just as effective?
Disease control Recruiting nowThis trial studies people with early-stage non-small cell lung cancer who are having surgery to remove the tumor. During surgery, doctors usually also remove lymph nodes from a specific area called station 4L. The trial randomly assigns half of the participants to have those lymp…
Sponsor: Fudan University • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New cancer drug TAK-505 enters first human trials
Disease control Recruiting nowThis study tests a new drug called TAK-505 in adults with advanced solid tumors that cannot be removed by surgery. The main goals are to check safety, find the best dose, and see if the drug can shrink or slow cancer growth. About 151 people with certain cancers, such as stomach,…
Phase 1/2 • Sponsor: Takeda • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New cancer drug BBO-10203 enters first human trials
Disease control Recruiting nowThis early-stage study tests a new drug called BBO-10203 in people with advanced solid tumors (breast, lung, or colorectal cancer) that have not responded to standard treatments. The drug is designed to block two cancer-driving proteins (PI3K and RAS). Researchers will check safe…
Phase 1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Promising drug targets lung cancer brain tumors in early trial
Disease control Recruiting nowThis study tests a drug called repotrectinib in 20 people with a specific type of lung cancer (ROS1-positive NSCLC) that has spread to the brain. The main goal is to see if the drug can shrink or eliminate brain tumors. Participants will take the drug by mouth, and doctors will m…
Phase 2 • Sponsor: MedSIR • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New COPD pill aims to cut dangerous lung attacks
Disease control Recruiting nowThis study tests an experimental tablet called AZD6793 in adults with moderate to very severe COPD. About 987 participants will take one of two doses of the drug or a placebo for 24 weeks. The goal is to see if the drug can reduce the number of serious flare-ups (exacerbations) c…
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug tarlatamab takes on tough lung cancers
Disease control Recruiting nowThis phase 2 trial is testing a drug called tarlatamab in 40 people with advanced small-cell lung cancer or other poorly differentiated neuroendocrine cancers. The drug is given by IV and aims to shrink tumors. Researchers will also study blood and tumor samples to understand why…
Phase 2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can a lupus drug protect lungs in connective tissue disease?
Disease control Recruiting nowThis study looks at the long-term safety and effectiveness of belimumab in adults with lung scarring (interstitial lung disease) caused by systemic sclerosis or other connective tissue diseases. About 514 people who completed earlier trials will receive belimumab for up to severa…
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Engineered immune cells take on Drug-Resistant lung cancer in first human trial
Disease control Recruiting nowThis early-phase study tests a new cell therapy called NK510 in 12 people with advanced non-small cell lung cancer that no longer responds to PD-1 inhibitors. The treatment uses specially designed natural killer cells that are blocked from a protein called TIGIT, aiming to boost …
Early phase 1 • Sponsor: Base Therapeutics (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New radioactive drug targets tough cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new radioactive drug, 225Ac-ETN029, in 116 adults with advanced DLL3-positive cancers like small cell lung cancer or neuroendocrine tumors. The main goal is to check safety and find the right dose, while also seeing if the drug can shrink tumors. Pa…
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New targeted pill aims to keep KRAS lung cancer from returning after surgery
Disease control Recruiting nowThis study tests whether the drug divarasib can prevent lung cancer from coming back in people with a specific gene mutation (KRAS G12C) who have already had surgery and chemotherapy. About 400 adults with stage II-III non-small cell lung cancer will be randomly assigned to recei…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New blood thinning combo could cut ECMO bleeding and clotting risks
Disease control Recruiting nowThis study tests a new way to manage blood thinning in patients on ECMO, a machine that helps the heart and lungs. The goal is to reduce bleeding and clotting problems, which affect over 40% of ECMO patients. Researchers will compare a combination of two blood thinners (nafamosta…
Sponsor: Beijing Chao Yang Hospital • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New antibody drug takes aim at autoimmune diseases
Disease control Recruiting nowThis early-stage study tests a new drug called SAR448501 (DR-0201) in 62 adults with lupus or rheumatoid arthritis. The drug is a bispecific antibody designed to target the immune system. The main goal is to check safety and find the right dose, not yet to prove it works. Partici…
Phase 1 • Sponsor: Sanofi • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New pill takes aim at hard-to-treat HER2 cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called IAM1363 in adults with advanced cancers that have HER2 alterations, including breast, lung, and stomach cancers that have spread to the brain. The study aims to find the safest dose and see if the drug can shrink tumors. About 383 pa…
Phase 1 • Sponsor: Iambic Therapeutics, Inc • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New nasal spray aims to stop asthma Flare-Ups triggered by common cold
Disease control Recruiting nowThis study tests a nasal spray called RIG-101 in healthy people and those with asthma. First, it checks safety and tolerability. Then, asthma participants receive the spray daily and are exposed to a cold virus to see if it prevents asthma worsening. The trial is recruiting 82 ad…
Phase 1/2 • Sponsor: RIGImmune Inc. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
BioNTech launches first human test of BNT317 against advanced cancers
Disease control Recruiting nowThis early-phase trial is testing a new experimental drug, BNT317, in 39 people with advanced solid tumors who have run out of standard treatment options. The main goal is to check the drug's safety, find the right dose, and see how the body handles it. It is too soon to know if …
Phase 1/2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New hope for tough lung cancer: dual-drug attack shows promise
Disease control Recruiting nowThis study tests two experimental drugs, MK-6070 and ifinatamab deruxtecan (I-DXd), alone or together, in people with advanced small cell lung cancer that stopped responding to standard treatment. The goal is to see if these combinations can shrink tumors and are safe. About 262 …
Phase 1/2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Phone-Based cholesterol coaching after heart attack shows promise
Disease control Recruiting nowThis study tests whether a proactive, pharmacist-led telephone program can help people who have had a heart attack reach safer cholesterol levels. Participants receive pharmacist calls, repeat blood tests, and medication adjustments based on national guidelines. The goal is to se…
Sponsor: University of Alberta • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New combo inhaler aims to cut severe asthma attacks in half
Disease control Recruiting nowThis phase 3 study tests whether an inhaler combining budesonide (a steroid) and albuterol (a rescue drug) works better than albuterol alone for preventing severe asthma attacks. About 790 Chinese adults with asthma who have had at least one severe attack in the past year will us…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New antibody M0324 enters first human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study is testing a new drug called M0324, a bispecific antibody designed to target cancer cells. The trial will look at M0324 alone, with the immunotherapy pembrolizumab, and with chemotherapy in about 77 people with advanced solid tumors that have not responded …
Phase 1 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can removing the primary tumor extend control in EGFR-Mutant lung cancer?
Disease control Recruiting nowThis phase III trial is investigating whether surgically removing the primary lung tumor, in addition to continuing the targeted therapy osimertinib, can prolong the time before disease progression in patients with EGFR-mutant non-small cell lung cancer that has spread to a limit…
Phase 3 • Sponsor: National Taiwan University Hospital • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Nanoparticles boost radiation against tough brain tumors
Disease control Recruiting nowThis study tests whether adding AGuIX gadolinium-based nanoparticles to standard brain radiation can better control brain metastases that are at high risk of coming back. About 134 adults with certain cancers (like melanoma, lung, breast, or colorectal) that have spread to the br…
Phase 2 • Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New injection aims to ease lung pressure in scarred lungs
Disease control Recruiting nowThis phase 2 trial tests an injected drug called TX000045 in 25 people who have high blood pressure in the lungs due to scarring lung disease. The main goal is to see if the drug lowers lung blood pressure and is safe over 16 weeks. Researchers will also check for side effects an…
Phase 2 • Sponsor: Tectonic Operating Company, Inc. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can a targeted pill after surgery keep early lung cancer from returning?
Disease control Recruiting nowThis study looks at whether taking the targeted drug icotinib after surgery helps people with early-stage non-small cell lung cancer that has EGFR mutations live longer. Researchers will compare patients who received icotinib after complete tumor removal with those who only had r…
Sponsor: Betta Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New hope for lung cancer patients with a specific gene mutation
Disease control Recruiting nowThis study tests a drug called divarasib, either alone or with other cancer treatments, in people with advanced lung cancer that has a specific genetic change (KRAS G12C). The goal is to see if the drug is safe and works to shrink or control the cancer. About 320 people who have …
Phase 1/2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can a new targeted drug shrink lung tumors?
Disease control Recruiting nowThis Phase II trial tests an experimental drug called SHR-1826 in about 300 people with advanced non-small cell lung cancer (NSCLC). The drug is given alone or combined with other cancer treatments to see if it can shrink tumors and improve outcomes. Researchers will also monitor…
Phase 2 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Could a Two-Drug combo reawaken the immune system against resistant cancers?
Disease control Recruiting nowThis trial tests whether combining bexmarilimab with nivolumab can help people whose cancers no longer respond to immunotherapy. It focuses on two cancers: non-small cell lung cancer and melanoma. The study first finds the safest dose of bexmarilimab to give with a fixed dose of …
Phase 1/2 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New drug TQB6411 aims to fight advanced lung cancer
Disease control Recruiting nowThis clinical trial is testing a new drug called TQB6411 in people with advanced lung cancer. The study has two phases: first to find the best dose, then to see how well it works. About 465 participants will receive the drug every 21 days. Researchers will measure tumor shrinkage…
Phase 1/2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New hope for KRAS lung cancer: targeted combo takes on chemo in major trial
Disease control Recruiting nowThis study tests whether a new drug (divarasib) combined with immunotherapy (pembrolizumab) works better than standard chemotherapy plus immunotherapy for people with a specific genetic mutation (KRAS G12C) in advanced non-small cell lung cancer. About 600 adults who have not had…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New shot aims to cut COPD attacks in half?
Disease control Recruiting nowThis Phase 2 trial tests an injection called RC1416 in 180 people with moderate to severe COPD. Participants will receive either the drug or a placebo to see if it reduces serious flare-ups and improves lung function over time. The study is double-blind, meaning neither patients …
Phase 2 • Sponsor: Nanjing RegeneCore Biotech Co., Ltd. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New antibody drug aims to turn immune cells against cancer
Disease control Recruiting nowThis early-stage study tests a new drug called NPX372 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to help the body's immune cells recognize and attack cancer cells. The main goals are to check the drug's safety and fin…
Phase 1 • Sponsor: NextPoint Therapeutics, Inc. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Exercise order may boost strength in COPD rehab
Disease control Recruiting nowThis trial investigates whether the sequence of endurance and strength exercises during pulmonary rehabilitation affects muscle strength in people with moderate to severe COPD. Participants are randomly assigned to do either strength training before endurance work or the reverse.…
Sponsor: CHU de Reims • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can a wrist sensor cut the dose of ICU muscle relaxants?
Disease control Recruiting nowThis trial tests whether a monitor that measures muscle response can guide the dose of the muscle relaxant atracurium in intensive care unit patients who need a continuous drip for more than 48 hours. Researchers will compare a group whose dose is adjusted using the monitor to a …
Sponsor: Fu Jen Catholic University Hospital • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New combo therapy aims to keep lung cancer from returning after surgery
Disease control Recruiting nowThis phase 3 trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy after surgery can help prevent non-small cell lung cancer from coming back. About 1,210 people with stage II to IIIB lung cancer will receive either chemo plus pembrolizumab toge…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New drug combo aims to tackle tough lung cancer mutation
Disease control Recruiting nowThis Phase 3 study tests whether adding olomorasib (a targeted pill) to standard immunotherapy (pembrolizumab or durvalumab) works better than immunotherapy alone for people with KRAS G12C-mutant non-small cell lung cancer. The trial has two parts: one for patients whose cancer w…
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New pill plus immunotherapy shows promise for tough lung cancer
Disease control Recruiting nowThis phase 3 study is testing whether adding an experimental pill called calderasib (MK-1084) to the immunotherapy drug pembrolizumab (Keytruda) works better than pembrolizumab alone for people with advanced non-small cell lung cancer that has a KRAS G12C mutation and high PD-L1 …
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New asthma drug could cut attacks with just two shots a year
Disease control Recruiting nowThis phase 3 trial tests whether GB-0895, given every 6 months, can reduce asthma attacks in adults and teens (ages 12–80) with severe asthma that isn't controlled by standard inhalers. About 786 participants will receive either GB-0895 or a placebo, and researchers will track ho…
Phase 3 • Sponsor: Generate Biomedicines • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New hope for KRAS lung cancer: major trial launches for targeted combo therapy
Disease control Recruiting nowThis global study is testing whether adding the experimental drug olomorasib to standard immunotherapy and chemotherapy can help people with a specific genetic subtype of advanced non-small cell lung cancer (KRAS G12C mutation). About 1,264 participants will receive either the ne…
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancers with genetic flaw
Disease control Recruiting nowThis study tests a new drug, LY4050784, in people with advanced solid tumors that have a specific change in the SMARCA4 gene. The goal is to see if the drug is safe and works, either alone or with other cancer treatments. About 340 adults whose cancer has not responded to standar…
Phase 1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New lung cancer drug pumitamig takes on standard therapy in major trial
Disease control Recruiting nowThis phase 3 trial compares a new drug called pumitamig to the standard drug pembrolizumab as a first treatment for people with advanced non-small cell lung cancer that has high levels of a protein called PD-L1 (at least 50%). The study will enroll 750 participants and measure ho…
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New study tracks how well alectinib keeps lung cancer from returning after surgery
Disease control Recruiting nowThis study follows 800 Chinese patients with early-stage ALK-positive non-small-cell lung cancer who took alectinib after surgery to see how long they stay cancer-free. Researchers will collect real-world data on disease-free survival and patient characteristics. The goal is to u…
Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New shot every 6 months could slash severe asthma attacks
Disease control Recruiting nowThis study tests a new medicine called GB-0895 for people aged 12 to 80 with severe asthma that is not controlled by standard inhalers. Participants receive either GB-0895 or a placebo as a shot every 6 months for a year. The goal is to see if GB-0895 can reduce the number of ser…
Phase 3 • Sponsor: Generate Biomedicines • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New hope for stiff lungs? drug trial targets scarring from autoimmune disease
Disease control Recruiting nowThis phase 3 trial tests whether belimumab (Benlysta) can stabilize or improve lung function in adults with interstitial lung disease caused by connective tissue diseases like rheumatoid arthritis or lupus. About 440 participants will receive either belimumab injections or a plac…
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Could a lupus drug help scleroderma lungs?
Disease control Recruiting nowThis study tests whether belimumab (Benlysta), a drug already used for lupus, can improve lung function and skin thickening in adults with scleroderma-related interstitial lung disease. About 300 participants will receive either belimumab or a placebo added to their standard care…
Phase 2/3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New lung cancer drug pumitamig takes on standard therapy in major trial
Disease control Recruiting nowThis phase 3 study compares the experimental drug pumitamig to the standard treatment durvalumab in people with stage III lung cancer that cannot be removed by surgery. Participants must have finished chemoradiation without their cancer getting worse. The main goal is to see if p…
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New inhaled drug aims to fight deadly lung scarring
Disease control Recruiting nowThis Phase 2 trial tests an experimental inhaled medication called LTI-03 in about 120 people with idiopathic pulmonary fibrosis (IPF), a progressive lung disease that causes scarring and breathing difficulty. Participants will inhale LTI-03 or a placebo twice daily for 24 weeks.…
Phase 2 • Sponsor: Rein Therapeutics • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New radioactive drug targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase trial tests a new radioactive drug, 177Lu-INN805, in 10 people with advanced solid tumors (like head & neck, lung, breast, or sarcoma) that haven't responded to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers wi…
Early phase 1 • Sponsor: FindCure Biosciences (ZhongShan) Co., Ltd. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New Antibody-Drug conjugate targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called LY4052031, which is designed to deliver a cancer-killing agent directly to tumor cells that have a protein called Nectin-4. The study includes 420 adults with advanced or metastatic solid tumors such as bladder, breast, lung, and oth…
Phase 1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Oxygen dilemma: which level saves preterm brains?
Disease control Recruiting nowThis study compares using 30% versus 60% oxygen when resuscitating extremely preterm babies (born before 29 weeks). The goal is to see which oxygen level leads to better survival and fewer long-term developmental problems like cerebral palsy or vision/hearing loss. About 1,200 ba…
Sponsor: University of Alberta • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New drug cocktail aims to tackle Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing a combination of two drugs—FC084CSA and tislelizumab—in people with advanced solid tumors that have stopped responding to standard treatments. The study aims to find the safest dose and see if the combo can control tumor growth. Only 33 participa…
Phase 1/2 • Sponsor: FindCure Biosciences (ZhongShan) Co., Ltd. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New hope for advanced lung cancer: experimental drug takes on chemo in major trial
Disease control Recruiting nowThis study compares an experimental drug (PF-08046054) to standard chemotherapy (docetaxel) in about 680 adults with advanced PD-L1 positive non-small cell lung cancer that has worsened after prior treatments. Participants are randomly assigned to receive one of the two drugs by …
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can short bursts of hard exercise ease bronchiectasis?
Disease control Recruiting nowThis study tests whether high-intensity interval exercise, short bursts of hard effort with rest in between, can help adults with non-cystic fibrosis bronchiectasis. Participants will either do this exercise plus airway clearance techniques, or only the clearance techniques, thre…
Sponsor: Saglik Bilimleri Universitesi • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New ECMO device tested for safe transport of critically ill patients
Disease control Recruiting nowThis study will test a new medical device kit (Novalung ultimate kit with Xenios 2.0) in 20 adult patients with severe heart-lung failure who need ECMO life support. The goal is to see if the device safely and effectively maintains blood oxygen levels during hospital use and grou…
Sponsor: Xenios AG • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a school program tame childhood asthma in san juan?
Disease control Recruiting nowThis trial tests a school-based asthma program for children aged 2 to 12 in San Juan, Puerto Rico, who have poorly controlled asthma. The program, delivered by community health workers, includes staff training, child education, and caregiver support. Researchers compare a high-in…
Sponsor: Rhode Island Hospital • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Spinal cord zap may help people breathe again after neck injury
Disease control Recruiting nowThis trial tests whether a device that sends mild electrical pulses to the spinal cord can help people with a cervical spinal cord injury breathe more independently. Twenty adults with a C1-C5 injury who need a ventilator will have electrodes implanted near the injury site and re…
Sponsor: Zhongda Hospital • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Could early treatment stop asthma before it gets severe?
Disease control Recruiting nowThis study tests whether the medication dupilumab can help people with moderate asthma achieve complete control (remission) when given early, before the disease becomes severe. About 150 adults aged 18-79 with moderate asthma and high inflammation markers will receive either dupi…
Phase 3 • Sponsor: Université de Sherbrooke • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a new drug shrink advanced solid tumors?
Disease control Recruiting nowThis trial tests an experimental drug called DS-2243a in adults with advanced solid tumors, including sarcoma, that have spread or cannot be removed surgically. The study has two parts: first, researchers find the safest dose by giving increasing amounts to small groups; then, th…
Phase 1 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New drug AVZO-1418 enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called AVZO-1418 in people with advanced solid tumors that have spread. The goal is to find a safe dose and see if it shrinks tumors. About 480 adults will take part, receiving the drug alone or with other treatments.
Phase 1/2 • Sponsor: Avenzo Therapeutics, Inc. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New hope for lung cancer patients: targeted drug Dato-DXd faces off against chemo
Disease control Recruiting nowThis phase 3 trial compares a new targeted drug, datopotamab deruxtecan (Dato-DXd), against the standard chemotherapy docetaxel in 400 people with advanced or metastatic non-squamous non-small cell lung cancer that lacks certain gene mutations. The goal is to see if Dato-DXd can …
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Last-Resort drug access opens for ALK-Positive cancer patients
Disease control Expanded accessThis program offers early access to the investigational drug neladalkib for people with advanced ALK-positive lung cancer or other ALK-positive solid tumors who have run out of standard treatment options and cannot join a clinical trial. Participants must be at least 18 years old…
Sponsor: Nuvalent Inc. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New hope for advanced cancers? pfizer launches early trial of PF-08046033
Disease control Recruiting nowThis early-stage study tests a new medicine called PF-08046033 in adults with advanced lung, esophageal, or skin cancers that have spread or can't be removed. The main goal is to check safety and find the right dose. Researchers will also look for early signs that the drug may he…
Phase 1 • Sponsor: Pfizer • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a new pill shrink tumors in EGFR-Mutant lung cancer?
Disease control Recruiting nowThis trial tests an experimental drug called CFT8919 in people with advanced non-small cell lung cancer that has an EGFR mutation. The goal is to find the safest dose and see whether the drug can shrink tumors. Participants take CFT8919 capsules twice daily and undergo regular ch…
Phase 1 • Sponsor: Betta Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Double drug attack on tough lung cancer shows promise
Disease control Recruiting nowThis study tests a combination of two targeted drugs—sotorasib and trastuzumab deruxtecan—in people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. The goal is to find the safest dose and see how well the combo works at shrinking tumors. About 37 …
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New hope for tough cancers: experimental drug IMGS-001 enters human trials
Disease control Recruiting nowThis early-stage study tests an experimental drug called IMGS-001 in about 105 people with advanced solid tumors that have come back or not improved after standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. The study has two parts: first, t…
Phase 1 • Sponsor: ImmunoGenesis • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis study tests a new drug, LY4170156, designed to attack cancer cells with a specific marker (folate receptor alpha). It is for people with advanced solid tumors like ovarian, lung, or breast cancer that have not responded to other treatments. The trial has two parts: first fin…
Phase 1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New trial aims to find best treatment for older lung cancer patients
Disease control Recruiting nowThis phase III trial compares adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in adults aged 70+ with advanced non-small cell lung cancer. The goal is to see if the combination improves survival. About 304 participants will be enrolled.
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a new immune therapy help frail lung cancer patients live longer?
Disease control Recruiting nowThis trial tests whether tarlatamab, a drug that helps the immune system attack cancer cells, can improve survival in people with advanced small-cell lung cancer whose general health is poor. The study includes 57 participants who have already had at least one prior treatment. Re…
Phase 2 • Sponsor: AIO-Studien-gGmbH • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New smart drug targets tough cancers in early trial
Disease control Recruiting nowThis early-phase study tests an experimental drug called PF-08046876 in about 310 adults with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas that have not responded to standard treatments. The drug is a type of 'antibody drug conjugate' designed to s…
Phase 1 • Sponsor: Pfizer • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New combo therapy aims to control lung cancer in First-Line patients
Disease control Recruiting nowThis study tests a new drug, BNT327, combined with chemotherapy and other agents in people with advanced non-small cell lung cancer who have not had prior treatment. The trial will enroll about 1,260 participants across multiple sites worldwide. The goal is to see if the combinat…
Phase 2/3 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New pill targets Hard-to-Treat cancers with MAPK gene flaw
Disease control Recruiting nowThis early-phase trial tests an experimental drug called D3S-002, taken as a daily pill, in adults with advanced solid tumors that have MAPK pathway mutations. The study has two parts: first, finding a safe dose, and second, testing that dose alone or with another drug (D3S-001) …
Phase 1/2 • Sponsor: D3 Bio (Wuxi) Co., Ltd • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Could an allergy drug tame COPD Flare-Ups?
Disease control Recruiting nowThis study tests if omalizumab (Xolair), an allergy drug, can reduce serious flare-ups in people with COPD who also have allergies. About 334 participants will receive injections of the drug or a placebo for 12 months. The goal is to see if the drug lowers the number of COPD exac…
Phase 2 • Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New cell therapy targets Hard-to-Treat cancers in first human trial
Disease control Recruiting nowThis early-stage study tests a new treatment called ZI-MA4-1, made from specially engineered immune cells, in people with advanced ovarian, lung, sarcoma, or head and neck cancers that have not responded to other therapies. The treatment aims to help the body's immune system atta…
Phase 1 • Sponsor: Zelluna Immunotherapy AS • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New pill targets Hard-to-Treat cancers with brain spread
Disease control Recruiting nowThis early-phase study tests a daily oral drug called CGT4255 in 100 adults with advanced solid tumors that have ERBB2 genetic changes or HER2 overexpression. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors, including in the brain. The …
Phase 1 • Sponsor: Cogent Biosciences, Inc. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Gentler exercise with a twist: could a tourniquet boost balance in lung disease?
Disease control Recruiting nowThis trial tests whether blood flow restriction (BFR) rehabilitation, which uses a pressure cuff during low-intensity resistance exercises, can improve functional mobility and balance in people with chronic obstructive pulmonary disease (COPD). Researchers will compare this appro…
Sponsor: Rashid Latif Medical College • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New pill shows promise against tough lung cancer
Disease control Recruiting nowThis study tests a new daily pill called TRI-611 for adults with advanced ALK-positive non-small cell lung cancer (NSCLC) that has not responded to other treatments. The trial has two parts: first, finding the safest dose, and second, seeing how well it shrinks tumors in differen…
Phase 1/2 • Sponsor: TRIANA Biomedicines, Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a team of doctors improve lung cancer care for seniors?
Disease control Recruiting nowThis study tests whether a team of specialists—including surgeons, oncologists, and geriatricians—can create better treatment plans for elderly lung cancer patients. 2,000 people aged 60-90 will receive personalized care based on their overall health and cancer type. The goal is …
Sponsor: West China Hospital • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug MK-4884 tested for safety in advanced cancers
Disease control Recruiting nowThis early-stage study tests a new drug called MK-4884 in about 120 people with advanced or metastatic solid tumors (colorectal, kidney, lung, or bile duct cancer). The main goal is to check the drug's safety and find the right dose. Researchers will monitor side effects and how …
Phase 1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Breakthrough asthma drug may let patients ditch puffers
Disease control Recruiting nowThis phase 3 trial is testing whether people with severe asthma who take the drug Tezepelumab can safely cut back on their other daily asthma medications without losing control of their symptoms. About 400 participants aged 12 to 80 will be enrolled. The goal is to see if they ca…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug IDP-001 takes on advanced cancers in early trial
Disease control Recruiting nowThis study tests an experimental drug called IDP-001 in people with advanced or metastatic solid tumors, including certain lung, head and neck, and other cancers. The trial has two phases: first to check safety and find the right dose, then to see if the drug can shrink tumors. A…
Phase 1/2 • Sponsor: InduPro, Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New targeted pill shows promise for tough lung cancer
Disease control Recruiting nowThis early-stage trial tests an experimental drug called BBO-8520 in 350 people with advanced non-small cell lung cancer that has a specific genetic change (KRAS G12C). The drug is taken as a pill and aims to block cancer growth. The study will check for safety, side effects, and…
Phase 1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New combo aims to control lung cancer that returns after standard therapy
Disease control Recruiting nowThis phase II trial tests whether adding local treatments like surgery or radiation to the immunotherapy drug durvalumab can help control stage III non-small cell lung cancer that has progressed after chemoradiation and durvalumab. About 51 participants with 3 or more growing tum…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug cocktail aims to extend life in tough lung cancer
Disease control Recruiting nowThis Phase 3 trial tests whether adding a maintenance drug (sacituzumab tirumotecan) after initial chemo-immunotherapy improves survival in people with metastatic squamous non-small cell lung cancer. About 851 participants will receive pembrolizumab plus chemotherapy, then either…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New biologic drug aims to cut COPD attacks in half
Disease control Recruiting nowThis Phase 3 study tests whether tezepelumab, a biologic drug, can reduce moderate to severe COPD flare-ups in adults aged 40-80. About 990 participants will receive either tezepelumab or a placebo as a shot under the skin. The main goal is to see if the drug lowers the number of…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New hope for rare cancer: oral pill targets early mesothelioma in High-Risk patients
Disease control Recruiting nowThis study tests an oral medication (decitabine/cedazuridine) in people with BAP1 gene mutations who have early-stage mesothelioma that is not yet causing symptoms. The goal is to see if the drug can stop the cancer from growing or shrink it. About 9 participants will receive tre…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug cocktail aims to shrink lung tumors before surgery
Disease control Recruiting nowThis phase 2 trial tests a combination of three drugs (tislelizumab, anlotinib, and nab-paclitaxel) given before surgery to people with stage III non-small cell lung cancer. The goal is to see if this approach can eliminate or greatly reduce the tumor before it is removed. The st…
Phase 2 • Sponsor: Qilu Hospital of Shandong University • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New lung drug faces off against standard treatment in major trial
Disease control Recruiting nowThis study tests a new drug, LYT-100, against an existing one (pirfenidone) for idiopathic pulmonary fibrosis, a lung disease that gets worse over time. About 1,100 adults will take either drug three times daily for up to a year, and researchers will measure how well their lungs …
Phase 3 • Sponsor: PureTech • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New shot could tame COPD Flare-Ups in severe patients
Disease control Recruiting nowThis Phase 3 trial tests whether tezepelumab, a biologic drug given as a shot, can reduce the number of moderate to severe COPD flare-ups in adults aged 40 to 80. About 990 participants with moderate to very severe COPD will receive either tezepelumab or a placebo for up to 76 we…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New hope for lung scarring: ABBV-142 enters Mid-Stage trial
Disease control Recruiting nowThis study tests an experimental drug called ABBV-142 in people with idiopathic pulmonary fibrosis (IPF), a rare lung disease that causes scarring and breathing problems. About 165 adults will receive either ABBV-142 or a placebo for 52 weeks to see if the drug is safe and can he…
Phase 2 • Sponsor: AbbVie • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Targeted radiation after lung cancer surgery aims to stop return
Disease control Recruiting nowThis study tests whether adding a precise type of radiation therapy (I²-PORT) after lung cancer surgery can help prevent the cancer from coming back. Participants have non-small cell lung cancer with remaining cancer in lymph nodes after initial treatment. The trial compares stan…
Phase 2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
BioNTech launches trial of BNT326 for advanced cancers
Disease control Recruiting nowThis study tests a new drug called BNT326, given alone or with other cancer immunotherapies, in about 980 adults with advanced solid tumors that have spread or come back after prior treatment. The goal is to find the best dose and see if it is safe and effective. It is an early-s…
Phase 1/2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug combo targets tough cancers in early trial
Disease control Recruiting nowThis early-phase trial is testing a new drug called KIN-2787 (exarafenib), alone or combined with another drug (binimetinib), in 400 adults with advanced solid tumors that have BRAF or NRAS mutations. The main goals are to check safety, find the best dose, and see if the drug can…
Phase 1 • Sponsor: Pierre Fabre Medicament • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Texts vs. manuals: new trial aims to help rural cancer survivors kick the habit
Disease control Recruiting nowThis study tests whether text-based support can help rural cancer survivors who smoke to quit. Participants will either receive text messages that gradually reduce cigarette use or a self-help manual. The goal is to see which approach works better for long-term smoking cessation.
Phase 3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New inhaled drug could help lung disease patients breathe easier and walk farther
Disease control Recruiting nowThis study tests an inhaled medicine called L606 for people with high blood pressure in the lungs due to lung disease. About 344 adults will be randomly assigned to receive L606 or a placebo. The main goal is to see if L606 helps them walk farther in six minutes and delays worsen…
Phase 3 • Sponsor: Liquidia Technologies, Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New hope for tough lung cancer: tarlatamab trial opens
Disease control Recruiting nowThis study tests a drug called tarlatamab in people with advanced small cell lung cancer that has worsened after one prior treatment. About 48 participants will receive the drug by IV to see if it helps them live longer. The goal is to find a new option for patients who have limi…
Phase 2 • Sponsor: ETOP IBCSG Partners Foundation • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New hope for tough lung cancer: expanded access to targeted drug
Disease control Expanded accessThis program provides early access to an experimental drug called ifinatamab deruxtecan (I-DXd) for people with extensive-stage small cell lung cancer who have already tried at least two prior treatments, including platinum-based chemotherapy. It is for patients who have no other…
Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug targets hard-to-treat cancers with missing MTAP gene
Disease control Recruiting nowThis early-stage trial tests an experimental drug called MRTX1719 in adults with advanced solid tumors that have a missing MTAP gene. The study aims to find a safe dose and see if the drug can shrink tumors or slow their growth. About 336 participants with cancers like mesothelio…
Phase 1 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New hope for tough lung cancer: targeted drug cocktails enter human testing
Disease control Recruiting nowThis study tests a new targeted therapy called MK-1084, alone or combined with other drugs, in 190 people with advanced non-squamous non-small cell lung cancer that has a specific KRAS G12C mutation and has worsened after prior treatments. The main goals are to check safety and s…
Phase 1/2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a needle at the knee supercharge lung cancer immunotherapy?
Disease control Recruiting nowThis trial tests whether adding electroacupuncture at a specific point below the knee, called Zusanli (ST36), to standard chemotherapy and immunotherapy can help shrink tumors in people with non-small cell lung cancer before surgery. The study includes 82 adults with this cancer …
Sponsor: West China Hospital • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New PET tracer could spot hidden fungal infections
Diagnosis Recruiting nowThis Phase 1 trial tests a new radioactive tracer called [18F]-Fluorocellobiose ([18F]FCB) for PET/CT scans. The goal is to see if it can help find invasive mold infections in the body. The study includes healthy volunteers and people with known fungal infections. Participants re…
Phase 1 • Sponsor: National Institutes of Health Clinical Center (CC) • Aim: Diagnosis
Last updated Sep 20, 2026 00:00 UTC
-
New scan could spot hidden scarring in heart and lungs before It's too late
Diagnosis Recruiting nowThis study tests a new radioactive tracer called 18F-FAPI-74 that may help detect scar tissue (fibrosis) in the heart and lungs earlier than current methods. Researchers will compare this new PET/CT scan to standard imaging in 210 adults with conditions like lung disease or heart…
Phase 3 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Diagnosis
Last updated Sep 20, 2026 00:00 UTC
-
One-Hour test could revolutionize pneumonia treatment in hospitals
Diagnosis Recruiting nowThis study compares a rapid test that identifies pneumonia-causing bacteria in about one hour to standard lab methods that take 2-4 days. Researchers want to see if the faster test helps doctors choose the right antibiotics sooner for 150 hospitalized patients with pneumonia. The…
Sponsor: Hospital de Clinicas de Porto Alegre • Aim: Diagnosis
Last updated Sep 19, 2026 00:00 UTC
-
Breathing tests face off: can extra lung measurements improve asthma diagnosis?
Diagnosis Recruiting nowResearchers compare how well different international asthma guidelines agree when diagnosing the condition in adults referred to a specialist lung service. They also check whether extra breathing tests not included in those guidelines, such as impulse oscillometry, detect airway …
Sponsor: Portsmouth Hospitals NHS Trust • Aim: Diagnosis
Last updated Sep 19, 2026 00:00 UTC
-
Can animals detect lung cancer by smell? a new study puts their noses to the test
Diagnosis Recruiting nowThis study explores whether a biosensor using trained laboratory animals can detect non-small cell lung cancer (NSCLC) by smelling unique chemicals in urine. Participants include people with and without NSCLC, as well as those suspected of having it. The goal is to see if this an…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Diagnosis
Last updated Sep 17, 2026 00:00 UTC
-
Can a PET scan reveal hidden heart harm from lung cancer treatment?
Diagnosis Recruiting nowThis trial is testing whether advanced PET-CT scans can spot early signs of heart damage caused by standard radiation therapy for locally advanced non-small cell lung cancer. Ten adults with stage III lung cancer will receive a special PET-CT scan before and three months after th…
Phase 2 • Sponsor: Indiana University • Aim: Diagnosis
Last updated Sep 17, 2026 00:00 UTC
-
AI trained to spot aggressive lung cancer before surgery
Diagnosis Recruiting nowResearchers are developing an artificial intelligence model that reads preoperative CT scans and clinical data to predict whether lung cancer associated with cystic airspaces has high-risk features. The study includes 600 patients with non-small cell lung cancer who had surgery a…
Sponsor: Central South University • Aim: Diagnosis
Last updated Sep 17, 2026 00:00 UTC
-
New portable device could speed up asthma diagnosis
Diagnosis Recruiting nowThis study aims to see if a portable device that measures lung function can accurately diagnose asthma in people with symptoms like wheezing or coughing. Researchers will compare this new test to the standard breathing tests currently used. The study plans to enroll 500 adults ac…
Sponsor: AstraZeneca • Aim: Diagnosis
Last updated Sep 16, 2026 00:00 UTC
-
Blood test aims to catch Cancer's return earlier
Diagnosis Recruiting nowThe ORACLE study watches people who have finished treatment for early-stage solid tumors, such as lung, breast, colon, and pancreatic cancers. Researchers want to see if a blood test called Guardant Reveal can find tiny traces of tumor DNA that might signal the cancer is coming b…
Sponsor: Guardant Health, Inc. • Aim: Diagnosis
Last updated Sep 16, 2026 00:00 UTC
-
Could a gentle breathing test replace hard blowing for Kids' asthma checks?
Diagnosis Recruiting nowDoctors often use a methacholine challenge to help diagnose asthma in children, but the standard breathing test requires strong cooperation and can fail if a child cannot blow hard enough. This study tests whether a gentler method called forced oscillation, which measures how the…
Sponsor: University Hospital, Montpellier • Aim: Diagnosis
Last updated Sep 13, 2026 00:00 UTC
-
Blood test aims to track cancer treatment response in real time
Diagnosis Recruiting nowResearchers are studying whether a blood test called Guardant360 can measure how well cancer treatment is working in people with advanced lung, colorectal, or breast cancer. The test looks for tumor DNA that cancer cells release into the bloodstream. Participants give blood sampl…
Sponsor: Guardant Health, Inc. • Aim: Diagnosis
Last updated Sep 13, 2026 00:00 UTC
-
Simple blood test could spot lung cancer early in heavy smokers
Diagnosis Recruiting nowThis study is testing a new blood test to find early-stage lung cancer in heavy smokers who have no symptoms. Researchers will collect blood samples from 350 current or former smokers aged 30-80, including those with and without lung cancer. The goal is to see if the test can det…
Sponsor: Everest Detection, Inc. • Aim: Diagnosis
Last updated Sep 13, 2026 00:00 UTC
-
Simple urine test could spot pneumonia in kids without needles
Diagnosis Recruiting nowThis study will test whether a new urine-based test can accurately diagnose pneumococcal pneumonia in children under 5 in Malawi. Researchers will use 350 stored urine samples from healthy kids and those with pneumonia, comparing results to standard lab methods. If it works, this…
Sponsor: Liverpool School of Tropical Medicine • Aim: Diagnosis
Last updated Sep 12, 2026 00:00 UTC
-
Can the ER become a front door for lung cancer screening?
Diagnosis Recruiting nowResearchers at Indiana University are testing an educational program called ED-LCS that teaches emergency department patients about lung cancer screening. The study enrolls adults aged 50 to 80 who have smoked at least 20 pack years and quit within the past 15 years, making them …
Sponsor: Indiana University • Aim: Diagnosis
Last updated Sep 12, 2026 00:00 UTC
-
Can a new tracer make tumors light up on scans?
Diagnosis Recruiting nowThis trial tests an experimental imaging agent called [68Ga]Ga-DWJ155 in adults with advanced cancers of the breast, lung, or stomach. The agent is designed to attach to tumor cells and show up on PET scans, helping doctors see where cancer has spread. Researchers will measure ho…
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Diagnosis
Last updated Sep 11, 2026 00:00 UTC
-
Laser and AI team up to spot lung cancer in minutes during surgery
Diagnosis Recruiting nowThis trial investigates whether a femtosecond laser combined with an artificial intelligence model can diagnose lung cancer from fresh tissue samples as accurately as the standard frozen section method. About 294 adults scheduled for lung surgery will have their tumor specimens e…
Sponsor: Shanghai Chest Hospital • Aim: Diagnosis
Last updated Sep 06, 2026 00:00 UTC
-
Weight loss could be key to spotting lung cancer sooner
Diagnosis Recruiting nowThis study looks at whether people with unexplained weight loss who are at high risk for lung cancer are more likely to develop the disease. Researchers will use low-dose CT scans and blood tests to screen 409 participants over one year. The goal is to see if adding weight loss t…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Diagnosis
Last updated Sep 06, 2026 00:00 UTC
-
Simple fluid test could replace needle biopsy for TB of the lung lining
Diagnosis Recruiting nowThis study tests a new liquid biopsy that measures TB DNA in fluid from around the lungs to diagnose tuberculous pleuritis, a common form of TB. Current methods often require invasive tissue biopsies or have low accuracy. The trial will enroll 350 adults with new-onset pleural ef…
Sponsor: Chinese University of Hong Kong • Aim: Diagnosis
Last updated Sep 05, 2026 00:00 UTC
-
Blood test breakthrough: AI reads platelets to spot lung cancer
Diagnosis Recruiting nowThis study aims to see if a new blood test can accurately detect lung cancer by analyzing RNA from platelets. Researchers will collect blood samples from 240 adults with lung cancer or suspicious lung nodules. The goal is to validate whether this AI-powered test can distinguish b…
Sponsor: University of Utah • Aim: Diagnosis
Last updated Sep 05, 2026 00:00 UTC
-
AI reads your heartbeat to catch silent killer in lung patients
Diagnosis Recruiting nowThis study tests whether an artificial intelligence (AI) tool that analyzes a simple ECG can help doctors find undiagnosed pulmonary hypertension (high blood pressure in the lungs) in people with interstitial lung disease. About 900 adults with severe lung scarring will be random…
Sponsor: Tempus AI • Aim: Diagnosis
Last updated Sep 04, 2026 00:00 UTC
-
Personalized navigation may boost cancer screening in high-risk communities
Prevention Recruiting nowThis study tests whether giving people a personalized report about their cancer risk and screening options helps them complete recommended cancer tests. Adults aged 45 to 74 who are at high risk for lung, breast, colorectal, upper gastrointestinal, or liver cancer are invited to …
Sponsor: Hunan Cancer Hospital • Aim: Prevention
Last updated Sep 20, 2026 00:00 UTC
-
Teaching Moms-to-Be about seafood safety: a new weapon against toxic exposures?
Prevention Recruiting nowThis study tests whether a prenatal education program can help pregnant women learn about and avoid toxic chemicals found in contaminated seafood. The program teaches about seafood benefits, risks, and safe handling. Researchers will measure changes in knowledge and whether women…
Sponsor: The University of Texas Medical Branch, Galveston • Aim: Prevention
Last updated Sep 16, 2026 00:00 UTC
-
Radiation before transplant: a new way to vaccinate against lung cancer?
Prevention Recruiting nowResearchers are testing whether giving targeted radiation to lung tumors before a lung transplant can create an immune response that helps the body fight cancer. The trial enrolls adults with end-stage lung disease and hard-to-treat lung cancer who need a transplant. The goal is …
Sponsor: Marc de Perrot • Aim: Prevention
Last updated Sep 12, 2026 00:00 UTC
-
Hope for High-Risk families: drug aims to stop lung scarring before it starts
Prevention Recruiting nowThis study tests a drug called nerandomilast in 80 people aged 40+ who have early lung changes and a family history of pulmonary fibrosis. Participants take either the drug or a placebo twice daily for up to 3 years. Doctors monitor lung function and scans to see if the drug slow…
Phase 3 • Sponsor: Boehringer Ingelheim • Aim: Prevention
Last updated Sep 10, 2026 00:00 UTC
-
A spoonful of olive oil before lung surgery: a new shield against a rare complication?
Prevention Recruiting nowThis trial tests whether drinking 40 mL of extra-virgin olive oil four hours before lung cancer surgery can reduce the risk of chylothorax, a rare but serious complication where lymphatic fluid leaks into the chest. About 1,036 adults with resectable lung cancer will be randomly …
Sponsor: Fudan University • Aim: Prevention
Last updated Sep 10, 2026 00:00 UTC
-
Can AI tailor recovery instructions after lung cancer surgery?
Symptom relief Recruiting nowResearchers are testing whether an AI-generated, personalized discharge plan improves the quality of discharge teaching and recovery for people who had lung cancer surgery. The trial enrolls 156 adults who had surgery for stage I to III lung cancer and are going home to recover. …
Sponsor: Xiamen University • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
Tiny One-Way valves for emphysema under close watch in japan
Symptom relief Recruiting nowResearchers in Japan are observing 140 people with severe emphysema who receive Zephyr Endobronchial Valves, tiny one-way valves placed in the lungs to reduce hyperinflation. The surveillance follows participants for 12 months across up to 20 centers. The main goal is to measure …
Sponsor: Pulmonx Corporation • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
New pain relief hope for lung cancer patients: nerve block via port
Symptom relief Recruiting nowThis study tests whether a nerve block given through a small port under the skin can help control chest pain in people with advanced lung cancer. The block delivers numbing medicine near the chest wall nerves. Researchers will compare pain levels and side effects in 180 patients …
Sponsor: Hanoi Medical University • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
New sedation cocktail may protect elderly hearts during ICU breathing support
Symptom relief Recruiting nowThis study compares two sedation methods for elderly ICU patients (65+) who need a breathing tube. One group gets a mix of propofol and ketamine, the other gets propofol alone. The goal is to see which causes fewer dangerous drops in blood pressure. The trial involves 41 particip…
Phase 3 • Sponsor: Helwan University • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
New study aims to find safer way to help preemies breathe
Symptom relief Recruiting nowThis study compares two methods of giving surfactant, a medicine that helps premature babies breathe. One method uses a thin tube, the other uses a small airway device. The goal is to see which method causes fewer breathing problems and complications in infants born at 29 weeks o…
Sponsor: University of Texas Southwestern Medical Center • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
New shot aims to ease depression and anxiety in cancer and chronic disease patients
Symptom relief Recruiting nowThis study tests whether a single injection of RE104 can reduce symptoms of depression or mixed depression and anxiety in people with adjustment disorder caused by a serious medical illness like cancer, ALS, multiple sclerosis, Parkinson's disease, or idiopathic pulmonary fibrosi…
Phase 2 • Sponsor: Reunion Neuroscience Inc • Aim: Symptom relief
Last updated Sep 17, 2026 00:00 UTC
-
Can inhaled saltwater help clear a stubborn lung infection?
Symptom relief Recruiting nowResearchers are testing whether inhaling a concentrated saltwater mist, added to standard supportive care, can improve quality of life and help clear Mycobacterium avium complex (MAC) bacteria from the lungs. The trial enrolls 30 adults with nodular-bronchiectatic MAC lung diseas…
Phase 4 • Sponsor: Radboud University Medical Center • Aim: Symptom relief
Last updated Sep 17, 2026 00:00 UTC
-
Two incisions or many? robotic lung cancer surgery put to the test
Symptom relief Recruiting nowResearchers compare two robotic surgery approaches for removing lung tumors in adults with non-small cell lung cancer. Participants are assigned at random to either biportal surgery, which uses two incisions, or multiportal surgery, which uses several small ports. The study track…
Sponsor: Carlos Déniz • Aim: Symptom relief
Last updated Sep 16, 2026 00:00 UTC
-
Can an antibiotic shorten chest tube time for cancer patients with lung fluid?
Symptom relief Recruiting nowThis study looks at two ways to treat malignant pleural effusion, a buildup of fluid in the lungs caused by cancer. One uses a small tube (indwelling pleural catheter) to drain fluid; the other adds the antibiotic doxycycline to help seal the lung. Researchers want to see if addi…
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 16, 2026 00:00 UTC
-
Can a nutrition plan help lung cancer patients stay stronger?
Symptom relief Recruiting nowResearchers are studying whether nutritional support helps people with advanced lung cancer maintain their weight, strength, and quality of life during chemotherapy. The trial enrolls 100 adults with high nutritional risk. Participants receive dietary advice or a structured nutri…
Sponsor: Casa di Cura Dott. Pederzoli • Aim: Symptom relief
Last updated Sep 16, 2026 00:00 UTC
-
Right care, right time: study tests smart palliative care model for heart failure and cancer
Symptom relief Recruiting nowThis study tests a flexible palliative care program for people with advanced heart failure or certain cancers. The program adds more team members—like a social worker or nurse—as symptoms get worse. The goal is to improve quality of life and match care to each person's changing n…
Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Symptom relief
Last updated Sep 16, 2026 00:00 UTC
-
Could a painkiller stop the cough that Won't quit in lung fibrosis?
Symptom relief Recruiting nowThis study tests whether an extended-release form of nalbuphine, a pain medication, can safely reduce chronic coughing in people with idiopathic pulmonary fibrosis (IPF), a lung scarring disease. About 306 adults with IPF and a cough lasting at least 8 weeks will receive either t…
Phase 3 • Sponsor: Trevi Therapeutics • Aim: Symptom relief
Last updated Sep 16, 2026 00:00 UTC
-
New radiation technique aims to ease lung cancer symptoms with fewer side effects
Symptom relief Recruiting nowThis study compares standard palliative radiation for lung tumors with a newer, more focused technique that delivers a higher dose while sparing the esophagus. The goal is to improve or maintain quality of life by better controlling symptoms and reducing side effects. About 141 a…
Sponsor: Chris Goodman • Aim: Symptom relief
Last updated Sep 16, 2026 00:00 UTC
-
Switching to a nebulizer may help COPD patients who get no relief from inhalers
Symptom relief Recruiting nowResearchers are testing whether COPD patients who report no symptom relief from their handheld maintenance inhalers do better when switched to nebulized versions of similar drugs. The trial enrolls about 120 people with severe COPD who have used a single handheld inhaler for at l…
Phase 4 • Sponsor: COPD Foundation • Aim: Symptom relief
Last updated Sep 16, 2026 00:00 UTC
-
Could a sleep apnea machine help people with collapsed airways?
Symptom relief Recruiting nowThis study looks at whether CPAP, a machine that pushes air through a mask at night, can help people with large airway collapse (LAC). LAC causes shortness of breath, cough, and wheeze, and is often mistaken for asthma. The study will test if a larger trial is possible by checkin…
Sponsor: Liverpool School of Tropical Medicine • Aim: Symptom relief
Last updated Sep 16, 2026 00:00 UTC
-
Amazon plant put to the test against Cancer's relentless tiredness
Symptom relief Recruiting nowCancer treatment often leaves patients with a deep, lasting tiredness that few treatments can fix. Researchers are testing whether guarana, a caffeine-rich Amazonian plant, can reduce that fatigue and improve daily life. The study gives 60 people with breast, lung, colorectal, ce…
Sponsor: Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
New app aims to bring palliative care to lung patients at home
Symptom relief Recruiting nowThis study tests a mobile app called SUPPORT-T that helps patients with progressive pulmonary fibrosis and their caregivers access palliative care from home. The app includes nurse-guided telehealth visits and virtual support groups over one year. Researchers want to see if the a…
Sponsor: Medical University of South Carolina • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
Cancer injection satisfaction study recruits 700 patients
Symptom relief Recruiting nowThis study observes about 700 people with lung or liver cancer who are already receiving atezolizumab as a shot under the skin. Researchers want to see how satisfied patients are with this treatment and how it affects their quality of life. The study does not test a new drug but …
Sponsor: Hoffmann-La Roche • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
New pill aims to shorten COPD Flare-Ups from common cold
Symptom relief Recruiting nowThis study tests an oral drug called vapendavir in 180 adults with COPD who catch a rhinovirus (common cold). The goal is to see if it can reduce the severity and length of breathing symptoms compared to a placebo. Participants are randomly assigned to one of two doses or a place…
Phase 2 • Sponsor: Altesa Biosciences, Inc. • Aim: Symptom relief
Last updated Sep 12, 2026 00:00 UTC
-
Can a breath of fresh oxygen boost exercise gains in COPD?
Symptom relief Recruiting nowPeople with COPD often lose stamina because their oxygen levels drop during exercise. This trial tests whether breathing extra oxygen through a nasal tube while doing a 3-month pulmonary rehabilitation program helps them exercise longer. Half the participants receive oxygen and h…
Sponsor: Eastern Switzerland University of Applied Sciences • Aim: Symptom relief
Last updated Sep 12, 2026 00:00 UTC
-
Smart wearables aim to speed up lung cancer surgery recovery
Symptom relief Recruiting nowThis study tests whether a wearable device and digital platform can help people recover better after lung cancer surgery. About 126 patients with non-small cell lung cancer will either use the wearable system or receive standard care. The system tracks heart rate, oxygen levels, …
Sponsor: West China Hospital • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
Can a breath of oxygen boost walking stamina in lung disease?
Symptom relief Recruiting nowThis trial asks whether breathing supplemental oxygen during a 6-minute walk test helps people with pulmonary vascular disease (PAH or CTEPH) walk farther than they would on ambient air. Participants will complete two walk tests—one with oxygen via nasal cannula and one without—t…
Sponsor: Silvia Ulrich Somaini • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
Wearables guide home prehab for older lung cancer patients
Symptom relief Recruiting nowResearchers are testing whether a home-based prehabilitation program can help older adults with non-small cell lung cancer prepare for surgery. The program combines aerobic exercise, breathing muscle training, functional and chest expansion exercises, nutrition guidance, and smok…
Sponsor: West China Hospital • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
Could a common numbing drug cut opioid needs in sickle cell emergencies?
Symptom relief Recruiting nowThis study tests whether adding lidocaine, a numbing medicine, to standard pain treatment can lower the amount of strong opioids needed during severe sickle cell pain crises. About 104 adults with sickle cell disease who are in the intensive care unit for a pain crisis will take …
Phase 3 • Sponsor: Nantes University Hospital • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
Can a breath of oxygen boost exercise capacity in pulmonary hypertension?
Symptom relief Recruiting nowThis trial tests whether breathing supplemental oxygen during exercise helps people with pulmonary vascular disease walk farther compared to breathing regular air. Participants will perform a standard six-minute walk test twice—once with oxygen and once without—to see if oxygen i…
Sponsor: Silvia Ulrich Somaini • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
New smartphone app aims to help asthma patients breathe easier
Symptom relief Recruiting nowThis study is testing a mobile app called ASTHMAXcel Voice to see if it helps adults with asthma better control their symptoms. The app sends reminders and educational content to users. Two hundred adults with persistent asthma will either use the app or receive usual care, and r…
Sponsor: Montefiore Medical Center • Aim: Symptom relief
Last updated Sep 10, 2026 00:00 UTC
-
Gentle exercise may revive energy in lung cancer patients
Symptom relief Recruiting nowThis trial tests whether low-intensity endurance exercise can reduce cancer-related fatigue and improve quality of life in lung cancer patients. Participants will either do continuous exercise or interval exercise for 30 minutes a day, five days a week, for 12 weeks. Researchers …
Sponsor: Taipei Medical University • Aim: Symptom relief
Last updated Sep 10, 2026 00:00 UTC
-
Pedal power: lung cancer patients try Pre-Radiotherapy exercise
Symptom relief Recruiting nowThis study tests whether a 20-minute exercise session on a stationary bike, done right before each radiotherapy treatment, is practical and safe for people with stage I-III non-small cell lung cancer. About 30 participants will try the program, and researchers will track how many…
Sponsor: Queen's University, Belfast • Aim: Symptom relief
Last updated Sep 10, 2026 00:00 UTC
-
Phone app aims to boost recovery in lung cancer patients
Symptom relief Recruiting nowThis study tests whether a smartphone app that tracks symptoms and gives feedback can help lung cancer patients do their prescribed rehab exercises after minimally invasive surgery. About 736 patients will use the app and be randomly assigned to get symptom alerts with clinician …
Sponsor: Zhongshan People's Hospital, Guangdong, China • Aim: Symptom relief
Last updated Sep 06, 2026 00:00 UTC
-
Mouthwash may stop cancer Drug's painful side effect
Symptom relief Recruiting nowThis study tests if a steroid mouthwash can prevent or reduce mouth sores caused by the cancer drug datopotamab deruxtecan (Dato-DXd). About 100 adults with advanced breast or lung cancer will use the mouthwash and be monitored for 12 weeks. The goal is to see if this simple step…
Phase 4 • Sponsor: AstraZeneca • Aim: Symptom relief
Last updated Sep 05, 2026 00:00 UTC
-
New inhaled drug hopes to clear lungs in mucus diseases
Symptom relief Recruiting nowThis early-stage study tests an inhaled drug called GDC-6988 in people with lung conditions that cause thick mucus, like non-CF bronchiectasis and COPD. The main goal is to check if the drug is safe and tolerable. About 128 adults with stable disease and good lung function will t…
Phase 1 • Sponsor: Genentech, Inc. • Aim: Symptom relief
Last updated Sep 04, 2026 00:00 UTC
-
App-based symptom tracking may cut hospital visits for advanced cancer patients
Symptom relief Recruiting nowThis trial tests a supportive web-based app for people with advanced pancreatic, biliary tract, or non-small cell lung cancer who are about to start their first line of chemotherapy. Each week, participants answer questions about their symptoms using the app. If their answers sug…
Sponsor: Inna Chen, MD • Aim: Symptom relief
Last updated Sep 04, 2026 00:00 UTC
-
Can alerts and training boost asthma treatment in kids?
Knowledge-focused Recruiting nowThis study tests whether giving doctors extra training and electronic reminders helps them prescribe a modern asthma treatment called SMART for children with moderate to severe asthma. The study involves 18 children ages 5 to 18 at primary care clinics. Researchers will compare h…
Sponsor: Children's Hospital of Philadelphia • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
New study aims to boost smart asthma care for children
Knowledge-focused Recruiting nowThis study tests two strategies to help doctors prescribe SMART therapy—a single inhaler for daily control and quick relief—for children with moderate to severe asthma. Researchers will use electronic reminders and education, plus a community health worker and nurse care manager,…
Sponsor: Children's Hospital of Philadelphia • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Heart safety of asthma drug tezepelumab under scrutiny in massive study
Knowledge-focused Recruiting nowThis study tracks over 16,000 teens and adults with severe asthma to see if the drug tezepelumab raises the risk of serious heart problems like heart attack, stroke, or heart-related death. Researchers will compare those taking tezepelumab to those on standard asthma treatments. …
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Scientists launch major study to unravel mysteries of rare lung infections
Knowledge-focused Recruiting nowThis study aims to learn more about non-tuberculous mycobacterial (NTM) infections, which cause repeated lung and other organ infections. Researchers will study up to 1,000 participants to understand the genetics, symptoms, and best treatments for these infections. The study also…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Do all kids with pneumonia need antibiotics? study tracks Real-World decisions
Knowledge-focused Recruiting nowResearchers are observing how often children hospitalized with non-severe pneumonia receive antibiotics and how doctors decide whether a child needs them. The study follows 200 children admitted to two German hospitals, recording treatment choices, medical complications, and pare…
Sponsor: ARCIM Institute Academic Research in Complementary and Integrative Medicine • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Can PET scan signals predict who beats lung cancer with immunotherapy?
Knowledge-focused Recruiting nowResearchers are investigating whether metabolic markers measured by PET/CT scans and tumor tissue tests can predict how well early-stage non-small cell lung cancer responds to immunotherapy given before surgery. Thirty patients with stage IB to IIIA NSCLC that lacks EGFR and ALK …
Phase 2 • Sponsor: Hospital das Clínicas de Ribeirão Preto • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Can restorative justice help close the lung cancer screening gap?
Knowledge-focused Recruiting nowThis study tests a decision-making support program based on restorative justice principles, designed specifically for Black adults who are at high risk for lung cancer. The goal is to see if this approach increases understanding, trust, and willingness to get screened. Forty-five…
Sponsor: Fred Hutchinson Cancer Center • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Lung cancer surgery registry aims to track Long-Term survival
Knowledge-focused Recruiting nowThis study is a registry that will follow 600 people with early-stage lung cancer who undergo a surgery called segmentectomy. Participants will fill out questionnaires about their health before surgery, shortly after, and six months later. The goal is to measure how long people l…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Can a new radiation machine cut breath holds for cancer patients?
Knowledge-focused Recruiting nowResearchers are studying whether a next-generation radiation delivery system can run a complete treatment workflow while patients hold their breath. The trial enrolls about 20 adults with tumors in the chest or upper abdomen who are already scheduled for stereotactic body radiati…
Sponsor: Varian, a Siemens Healthineers Company • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Can a COPD flare stun the heart? study watches for hidden strain
Knowledge-focused Recruiting nowResearchers at Sahlgrenska University Hospital in Sweden are observing 200 adults hospitalized for a severe COPD flare-up to see how often the condition triggers a temporary heart muscle weakness called Takotsubo stunning. They will use echocardiograms to check heart function at …
Sponsor: Sahlgrenska University Hospital • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Patients and families build a living database of pulmonary fibrosis
Knowledge-focused Recruiting nowThe Pulmonary Fibrosis Foundation runs an online registry where people with pulmonary fibrosis or interstitial lung disease, their caregivers, and their family members can share information about their health and experiences. Participants enroll themselves and answer questions ov…
Sponsor: Pulmonary Fibrosis Foundation • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Can wearables unlock the link between fatigue and movement in lung cancer?
Knowledge-focused Recruiting nowThis observational study follows 50 adults with locally advanced or metastatic lung cancer who are starting chemotherapy or immunotherapy. Researchers want to see how cancer-related fatigue and daily physical activity change during treatment, and whether those changes are connect…
Sponsor: University Hospital, Ghent • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Scientists launch major study to unravel salivary gland mysteries
Knowledge-focused Recruiting nowThis study aims to learn more about diseases that affect the salivary glands, which produce saliva. Researchers will collect medical data, blood, saliva, and tissue samples from people with these conditions, their relatives, and healthy volunteers. The goal is to better understan…
Sponsor: National Institute of Dental and Craniofacial Research (NIDCR) • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Can sensing your body's signals ease COPD symptoms?
Knowledge-focused Recruiting nowThis study looks at how well people hospitalized for a COPD flare-up perceive internal body signals — a skill called interoception — and whether that relates to their breathlessness, depression, and sleep quality. Researchers will assess 50 patients using questionnaires and clini…
Sponsor: Saglik Bilimleri Universitesi • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Six biologics put to the test in Real-World asthma and COPD care
Knowledge-focused Recruiting nowResearchers are observing how six biologics that target Type 2 inflammation perform in adults with asthma or COPD during routine care in China. The study follows 538 participants for 12 months to measure flare-ups, lung function, symptom control, and safety. It also collects bloo…
Sponsor: Shanghai Pulmonary Hospital, Shanghai, China • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Massive study seeks to unlock how your surroundings and DNA shape disease risk
Knowledge-focused Recruiting nowThis study looks at how your genes and your environment—like what you eat, breathe, and experience—work together to influence common diseases such as diabetes, heart disease, and asthma. Researchers are collecting health questionnaires, genetic data, and other information from 25…
Sponsor: National Institute of Environmental Health Sciences (NIEHS) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Can a blood test tell which lung cancer patients can skip chemo?
Knowledge-focused Recruiting nowResearchers are studying whether a blood test that looks for tiny traces of cancer DNA can identify early-stage lung cancer patients who are unlikely to need extra treatment after surgery. The trial enrolls adults with stage IB to IIIA non-small cell lung cancer who have had comp…
Sponsor: Guangdong Association of Clinical Trials • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Can personalized chemoradiation protect lung cancer Patients' hearts?
Knowledge-focused Recruiting nowThis study looks at how chemoradiation for locally advanced lung cancer affects the heart. Researchers will track 100 patients using heart tests, blood samples, and questionnaires. The goal is to see if tailoring treatment based on individual risk can reduce heart problems.
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Scientists hunt for protein clues to Pneumonia's hidden causes
Knowledge-focused Recruiting nowThis study looks at proteins in lung fluid from 750 people with pneumonia to find biomarkers that could reveal what's causing the lung inflammation. Participants undergo a standard bronchoscopy with lung washings, plus a blood draw. The goal is to better understand different type…
Sponsor: National Institutes of Health Clinical Center (CC) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Scientists probe immune System's role in chronic disease
Knowledge-focused Recruiting nowThis study looks at how the body's innate immune system responds to certain environmental exposures by measuring inflammation markers in blood. Researchers will collect blood samples from up to 725 healthy volunteers aged 18-45 to analyze how specific genes and proteins react. Th…
Sponsor: National Institute of Environmental Health Sciences (NIEHS) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
The hidden breath: how a mismatch between patient and machine may shape ARDS recovery
Knowledge-focused Recruiting nowResearchers at Hospital Civil de Guadalajara are observing mechanically ventilated patients with acute respiratory distress syndrome (ARDS) to measure how often a breathing mismatch called reverse trigger occurs. They monitor patients continuously with esophageal manometry from t…
Sponsor: Hospital Civil de Guadalajara • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Rare cancer syndrome under the microscope: what families need to know
Knowledge-focused Recruiting nowThis study follows people with a rare genetic condition called DICER1 syndrome, which raises the risk of certain childhood cancers like pleuropulmonary blastoma. Researchers will collect medical histories, genetic samples, and tissue from up to 1,500 participants and their relati…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
NIH launches Long-Term study to uncover clues in rare lung disease
Knowledge-focused Recruiting nowThis natural history study follows 270 adults with pulmonary arterial hypertension (PAH) and healthy volunteers to track how the disease changes over time. Researchers will use blood tests, heart and lung imaging, and a six-minute walk test to find new markers of disease severity…
Sponsor: National Institutes of Health Clinical Center (CC) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Massive greek health study aims to unmask COPD-Heart disease link
Knowledge-focused Recruiting nowThis study is observing 900 adults in Greece who have both chronic obstructive pulmonary disease (COPD) and at least one heart condition. Researchers will track their health for two years, recording lung flare-ups, heart complications, hospital visits, and quality of life. The go…
Sponsor: Hellenic Thoracic Society • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Sickle cell study aims to uncover disease patterns
Knowledge-focused Recruiting nowThis study follows up to 3,500 people with sickle cell disease to learn more about how the condition progresses and what complications arise. Participants receive their usual medical care outside the hospital and visit the clinic for check-ups and research tests. No experimental …
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Scientists dive deep into the roots of a mysterious lung disease
Knowledge-focused Recruiting nowThis study aims to understand how lymphangioleiomyomatosis (LAM) damages the lungs at the cellular and genetic level. Researchers will follow up to 2,000 participants, including women with LAM and healthy volunteers, using advanced imaging and lab tests. The goal is to find the p…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Rare gene study aims to unlock kidney cancer risks
Knowledge-focused Recruiting nowThis study looks at a rare inherited condition called Birt-Hogg-Dube (BHD) syndrome, which raises the risk of kidney cancer. Researchers will collect blood, saliva, and tissue samples from up to 950 participants to find the genes involved and understand how kidney tumors grow. Th…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Scientists seek clues on white blood cell behavior in allergies and parasites
Knowledge-focused Recruiting nowThis study aims to understand how and why eosinophils (a type of white blood cell) become active in conditions like allergies, asthma, and parasitic infections. Researchers will observe up to 800 people aged 1 to 100 with high eosinophil levels. No experimental treatments are giv…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
New study tracks safety of enzyme therapy in babies with rare genetic disease
Knowledge-focused Recruiting nowThis study follows up to 10 children under 2 years old with acid sphingomyelinase deficiency (ASMD) who are already receiving olipudase alfa (Xenpozyme®) as part of their routine care. Researchers will monitor side effects and immune responses over 1 to 3 years. No new treatment …
Sponsor: Sanofi • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
AI assistant for chest X-Rays: can it spot what doctors miss?
Knowledge-focused Recruiting nowThis study tests whether an AI tool called LuAna helps doctors find lung problems in chest X-rays more accurately than doctors working alone. About 1,470 adults with breathing issues will have their X-rays read first by doctors, then with AI support. The goal is to see if AI boos…
Sponsor: Hospital Israelita Albert Einstein • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Scientists collect tissue to unlock lung cancer secrets
Knowledge-focused Recruiting nowThis study collects tissue samples and health information from 2000 adults with certain lung and thymic cancers. Researchers aim to better understand these diseases, which could lead to new diagnostic tools and treatments. Participants provide blood, tumor samples, and imaging da…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Ventilator Patients' diaphragm decline measured in new study
Knowledge-focused Recruiting nowThis study tracks how quickly the diaphragm weakens in 15 ICU patients on mechanical ventilation. Researchers use advanced muscle tests and brain stimulation to measure changes in diaphragm function and control. The goal is to better understand ventilator-induced diaphragm dysfun…
Sponsor: RWTH Aachen University • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
New registry aims to map treatment landscape for rare lung cancer mutation
Knowledge-focused Recruiting nowThis study is a disease registry that will follow about 700 people with advanced non-small cell lung cancer that has a specific genetic change called METex14 skipping. Researchers will collect information on patient characteristics, treatments, and outcomes over time to better un…
Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Morning or afternoon? new study tests if immunotherapy timing boosts cancer fight
Knowledge-focused Recruiting nowThis study looks at whether getting immunotherapy infusions in the morning versus the afternoon changes outcomes for people with advanced lung cancer or head and neck cancer. About 238 participants will be randomly assigned to morning or afternoon infusions. Researchers will trac…
Phase 2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Can pulmonary fibrosis patients pull hard enough for their inhalers?
Knowledge-focused Recruiting nowResearchers at Shanghai Pulmonary Hospital are studying how much breathing force people with idiopathic or progressive pulmonary fibrosis can generate through inhaler devices of different resistances. Sixty participants will use a handheld tool called the In-Check DIAL G16, which…
Sponsor: Shanghai Pulmonary Hospital, Shanghai, China • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Scientists hunt for hidden subgroups in sudden respiratory failure
Knowledge-focused Recruiting nowResearchers at Evangelismos Hospital are studying adults who arrive in the emergency department with sudden acute hypoxemic respiratory failure, a condition where the blood oxygen drops dangerously low. The team collects clinical, imaging, physiological, and biological data early…
Sponsor: Evangelismos Hospital • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Can a Preemie's NICU breathing pattern predict asthma and sleep problems years later?
Knowledge-focused Recruiting nowResearchers want to know if breathing patterns recorded while premature babies are in the neonatal intensive care unit relate to asthma, sleep-disordered breathing, and neurodevelopmental problems at preschool age. The study follows up to 500 children born before 29 weeks of preg…
Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
New radiation technique aims to protect heart in thoracic cancer patients
Knowledge-focused Recruiting nowThis study tests whether a newer, MRI-guided radiation method (MRgART) is gentler on the heart than standard radiation (LINAC) for people with lung, esophageal, or other chest cancers. About 60 adults will receive radiation and have their heart function checked via MRI and blood …
Phase 2 • Sponsor: University of Wisconsin, Madison • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Robotic lung surgery on the rise: what does it mean for patients?
Knowledge-focused Recruiting nowThis study reviews medical records from 600 lung cancer patients who had surgery between 2004 and 2019. The goal is to see if the use of robotic surgery has led to more atypical segmentectomies (removing part of a lung lobe). Researchers want to understand how robotic methods com…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
Chatbot vs. paper: which teaches caregivers better?
Knowledge-focused Recruiting nowThis study tests whether a chatbot called 'Pneumonia Care Helper' can improve the knowledge, attitudes, and caregiving skills of people caring for elderly pneumonia patients. 150 caregivers will either use the chatbot with educational videos for 5 days or receive standard paper i…
Sponsor: Taipei Veterans General Hospital, Taiwan • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
Robot vs video: which lung cancer surgery is better for recovery?
Knowledge-focused Recruiting nowThis study compares two types of minimally invasive lung cancer surgery: robotic-assisted (RATS) and video-assisted (VATS). It will follow 512 patients across Europe to see which technique leads to better quality of life and recovery. The goal is to help surgeons and patients mak…
Sponsor: Intuitive Surgical • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
Scleroderma's hidden link: could pelvic floor trouble track with weaker lungs?
Knowledge-focused Recruiting nowScleroderma often scars the lungs, which can weaken breathing muscles and make exercise harder. Researchers want to know whether pelvic floor problems, such as incontinence or pelvic pain, go hand in hand with these lung and breathing changes. The study enrolls 67 women with scle…
Sponsor: Biruni University • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
New study aims to find best breathing support for COPD patients during lung surgery
Knowledge-focused Recruiting nowThis study looks at how different ventilator pressure settings affect breathing and heart function in people with COPD undergoing lung surgery. Forty-eight patients will each try three short pressure settings in random order. The goal is to find which setting keeps the lungs open…
Sponsor: Samsung Medical Center • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
Can a smartwatch track how kids recover from cancer surgery?
Knowledge-focused Recruiting nowThis study is testing whether smartwatches and blood tests can measure how well children recover after surgery to remove a solid tumor. About 40 children and their caregivers will wear smartwatches and answer questionnaires before surgery and for up to a year after. Researchers w…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
Brazil launches major study to track severe COPD outcomes
Knowledge-focused Recruiting nowThis study will follow 693 people in Brazil with severe or very severe COPD to track how often they are hospitalized, have flare-ups, or die. Researchers want to understand the real-world impact of the disease in this group. No new treatments are being tested—only data is collect…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
Researchers track lung cancer care in china
Knowledge-focused Recruiting nowThis study looks at medical records of 3000 people in China with early-stage non-small cell lung cancer (stages I to III). The goal is to understand what treatments patients receive, how often biomarker testing is done, and what happens to them over time. No new treatments are gi…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
Laser imaging may uncover secret triggers of lung disease
Knowledge-focused Recruiting nowThis study explores whether a technique called LIBS, which maps chemical elements in lung tissue, can help doctors identify possible environmental or workplace causes of chronic lung diseases. Researchers will analyze stored biopsy samples from 70 adult patients using LIBS and an…
Sponsor: University Hospital, Grenoble • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
New study aims to map healthy lungs with advanced imaging and breathing tests
Knowledge-focused Recruiting nowThis study will observe how healthy lungs work by using two non-invasive tests: a special MRI that shows lung ventilation and a breathing test that measures airway resistance. Twenty healthy adults will participate to help researchers understand the relationship between these mea…
Sponsor: University of Rochester • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
Large study to count hidden dangers of nerve blocks
Knowledge-focused Recruiting nowThis observational study will follow about 3,400 adults receiving single-shot regional anesthesia (nerve blocks) for surgery. Researchers aim to measure how often complications like nerve injury, bleeding, or lung puncture occur. The study does not test any new drug or treatment—…
Sponsor: Societa Italiana Anestesia Analgesia Rianimazione e Terapia Intensiva • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
Scientists hunt for lung disease genes in 3,500 volunteers
Knowledge-focused Recruiting nowThis study looks at how genes play a role in lung diseases like cystic fibrosis, asthma, and pulmonary fibrosis. Researchers will examine DNA from up to 3,500 people with and without lung disease to find genetic differences. The goal is to better understand what causes these cond…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
Which exercise is better for the COPD brain? scientists compare steady vs. burst workouts
Knowledge-focused Recruiting nowThis study looks at how two different exercise styles—steady moderate cycling versus short, intense bursts—affect brain oxygen levels, breathing, and heart function in people with COPD. Researchers will measure changes in brain oxygenation and other body responses during rest, ex…
Sponsor: George Papanicolaou Hospital • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
Study aims to cut unnecessary doctor visits for kids with bronchiolitis
Knowledge-focused Recruiting nowThis study looks at two different approaches to help doctors and families avoid unnecessary follow-up visits after a child is hospitalized for bronchiolitis. About 2,700 children will take part to see which method works better at encouraging follow-up only when needed. The goal i…
Sponsor: Seattle Children's Hospital • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
New study aims to catch lung cancer early in french smokers
Knowledge-focused Recruiting nowThis study looks at whether a structured program can help more high-risk smokers get a first lung cancer screening with a CT scan. About 500 people aged 50 to 74 who smoke or recently quit will join. The goal is to see if a dedicated network makes screening easier and more effect…
Sponsor: Institut Curie • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
Scientists launch deep dive into rare bleeding and lung disease
Knowledge-focused Recruiting nowThis study aims to learn more about Hermansky-Pudlak Syndrome (HPS), a rare inherited disease that causes light skin/eye color, bleeding problems, and often deadly lung scarring. Researchers will follow 600 people with HPS and their family members to track how the disease progres…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Sep 11, 2026 00:00 UTC
-
Massive study aims to standardize lung cancer testing across labs
Knowledge-focused Recruiting nowThis study involves 3,400 people with advanced non-small cell lung cancer to see if a new test for a protein called TROP2 works consistently across different laboratories. The goal is to ensure that doctors can reliably use this test to guide treatment decisions. Participants pro…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Sep 11, 2026 00:00 UTC
-
Could a quick CPAP boost help preterm babies breathe better?
Knowledge-focused Recruiting nowThis study tests whether briefly increasing the air pressure from a CPAP machine before giving surfactant therapy helps preterm babies' lungs work better. Surfactant is a natural substance that helps immature lungs stay open, and it's often given through a thin tube. The trial wi…
Sponsor: Murdoch Childrens Research Institute • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
Scientists hunt for genetic clues in lung and esophageal cancers
Knowledge-focused Recruiting nowThis study aims to collect tumor, normal tissue, and blood samples from up to 1559 people with cancers of the lung, esophagus, or pleura. Researchers will analyze genetic and epigenetic changes to better understand these diseases and identify potential markers for future treatmen…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
Asthma under the microscope: 2,500 patients enrolled in landmark Real-World study
Knowledge-focused Recruiting nowThis study is observing 2,500 people with asthma to learn more about their symptoms, treatments, and quality of life in everyday settings. Participants will fill out surveys and may provide blood samples or lung function tests. The goal is to better understand how asthma affects …
Sponsor: Sanofi • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
ER Check-Ups could boost lung cancer screening rates
Knowledge-focused Recruiting nowThis study tests a new way to increase lung cancer screening in people at high risk. Researchers will use the emergency department to identify eligible patients and offer them extra help to get a low-dose CT scan. The goal is to see if this approach works better than standard car…
Sponsor: Hackensack Meridian Health • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
Can drug monitoring make a common lung cancer treatment safer and more effective?
Knowledge-focused Recruiting nowThis study is looking at whether regularly checking the amount of pembrolizumab in the blood of people with non-small cell lung cancer can help doctors tailor treatment. The goal is to see if this monitoring can improve how well the drug works and reduce side effects. The trial w…
Sponsor: University Hospital, Angers • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
Can protein patterns in stored tumors point to new treatment targets?
Knowledge-focused Recruiting nowThis observational study in Vietnam looks at archived tumor samples from patients with several solid cancers, including liver, colorectal, gastric, breast, lung, endometrial, melanoma, and pancreatic cancer. Researchers will measure the presence of two proteins, ENPP1/cGAS and FA…
Sponsor: Tam Anh Research Institute • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
Robotic biopsies help unlock lung cancer genetics for future research
Knowledge-focused Recruiting nowThis study looks at how well robotic biopsies can collect enough tissue to find genetic changes linked to lung cancer. About 40 adults at high risk for lung cancer or with suspected spread to the lungs will take part. The goal is to create a databank of genetic and medical inform…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
New study maps cancer treatment journeys across latin america
Knowledge-focused Recruiting nowThis study looks back at medical records of 200 adults in Latin America with a rare and aggressive cancer called neuroendocrine carcinoma. Researchers want to understand how patients are diagnosed, what treatments they receive, and how their disease progresses over time. The goal…
Sponsor: Latin American Cooperative Oncology Group • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
NCI opens screening study for experimental cell therapies in multiple cancers
Knowledge-focused Recruiting nowThis study screens adults with certain cancers (like melanoma, lung, or colorectal cancer) to see if they qualify for experimental treatments being tested by the NCI Surgery Branch. These treatments involve taking a patient's own immune cells, growing them in a lab, and giving th…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
Can rehabilitation boost confidence in fibrotic lung disease?
Knowledge-focused Recruiting nowThis observational study follows patients with fibrotic interstitial lung disease (ILD) to see how their self-efficacy and quality of life change over time. Participants either undergo inpatient pulmonary rehabilitation or receive regular outpatient care. Researchers use question…
Sponsor: Berner Reha Zentrum AG • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
New study aims to better classify lung tumors with air pockets
Knowledge-focused Recruiting nowThis study looks at 500 people with a rare type of lung cancer that has air-filled pockets (cysts). Researchers want to find the best way to measure these tumors to improve staging and predict outcomes. By reviewing past CT scans and health records, they hope to help doctors make…
Sponsor: Central South University • Aim: Knowledge-focused
Last updated Sep 06, 2026 00:00 UTC
-
New study gathers key materials to create personalized cell therapies for tough cancers
Knowledge-focused Recruiting nowThis observational study collects tumor tissue and blood cells from 200 people with advanced solid tumors like colorectal, lung, and pancreatic cancers. The goal is to understand how often tumors lose a specific marker (HLA) and to store participants' own T cells for potential fu…
Sponsor: A2 Biotherapeutics Inc. • Aim: Knowledge-focused
Last updated Sep 05, 2026 00:00 UTC
-
Massive canadian study tracks lung cancer care and costs
Knowledge-focused Recruiting nowThis study will review health records of 60,000 adults with lung cancer in Alberta and Ontario to understand current treatments, survival rates, and healthcare costs. It aims to describe real-world patterns rather than test a new treatment. No direct benefit to participants, but …
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Sep 05, 2026 00:00 UTC
-
Lying flat or upright? study tests best position for ARDS breathing
Knowledge-focused Recruiting nowThis study looks at how tilting the body (trunk inclination) changes lung mechanics in 40 adults with moderate to severe ARDS who are on ventilators. Researchers will measure lung pressures and use electrical imaging to see how different positions and ventilator settings affect l…
Sponsor: Zhongda Hospital • Aim: Knowledge-focused
Last updated Sep 05, 2026 00:00 UTC
-
Moscow COPD patients under the microscope: new study tracks Real-World care
Knowledge-focused Recruiting nowThis study will collect information from about 500 adults in Moscow who have moderate to very severe COPD and have had frequent flare-ups. Researchers will look at their medical history, current treatments, and overall health to better understand the disease and how it is managed…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Sep 05, 2026 00:00 UTC
-
Tailoring ventilators to each Patient's lungs: a new hope for ARDS?
Knowledge-focused Recruiting nowThis study looks at how to adjust breathing machine settings for people with moderate-to-severe ARDS, a serious lung condition. Researchers will use a special imaging technique to see how air and blood flow match up in the lungs. The goal is to find the best settings for each pat…
Sponsor: Zhongda Hospital • Aim: Knowledge-focused
Last updated Sep 05, 2026 00:00 UTC
-
Reading the machine's breath: a new way to foresee post-surgery lung failure?
Knowledge-focused Recruiting nowThis study at West China Hospital follows 250 adults who need a breathing machine after major surgery. Researchers will record the machine's waveforms, which show how air moves in and out of the lungs, and check whether certain patterns warn of respiratory failure. The goal is to…
Sponsor: West China Hospital • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
AI tool aims to keep COPD patients on track after emergency
Knowledge-focused Recruiting nowThis study looks at whether a smart computer program (AI) can help doctors make sure people with COPD see a lung specialist within 30 days after leaving the hospital. About 485 adults who had a serious COPD flare-up will take part. The goal is to see if the AI tool improves follo…
Sponsor: Viz.ai, Inc. • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
Can Immunotherapy's hidden toll on daily life be measured?
Knowledge-focused Recruiting nowThis study follows 75 people with locally advanced non-small cell lung cancer who receive a year of adjuvant immunotherapy after chemoradiotherapy. Researchers will use questionnaires to track changes in quality of life and self-reported health from the start of immunotherapy to …
Sponsor: Göteborg University • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC